resorcinols - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	resorcinols	go back to main search page
Accession:	CHEBI:33572	browse the term
Definition:	Any benzenediol in which the two hydroxy groups are meta to one another.

show annotations for term's descendants Sort by:
Rat (7353) Mouse (7469) Human (7892) Chinchilla (0) Bonobo (0) Dog (16) Squirrel (0) Pig (488) Green Monkey (0) Naked Mole-rat (0) All
Genes (488)

kuwanone G

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

pancreatic lipase

decreases activity
multiple interactions

kuwanon G results in decreased activity of PNLIP protein
kuwanon G inhibits the reaction [PNLIP protein results in increased hydrolysis of 4-methylumbelliferyl oleate]

NCBI chr14:126,771,920...126,789,097
Ensembl chr14:126,772,911...126,790,001

resveratrol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin binding LIM protein 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of ABLIM1 mRNA

NCBI chr14:124,759,811...125,108,722
Ensembl chr14:124,760,404...125,010,892

G

aggrecan

decreases degradation

Resveratrol results in decreased degradation of ACAN protein

NCBI chr 7:54,449,830...54,520,606
Ensembl chr 7:54,449,816...54,519,194

G

androglobin

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of ADGB mRNA

NCBI chr 1:18,870,880...19,030,983
Ensembl chr 1:18,870,884...19,029,417

G

adhesion G protein-coupled receptor D1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ADGRD1 mRNA]

NCBI chr14:24,059,667...24,241,270
Ensembl chr14:24,059,019...24,241,176

G

AT-rich interaction domain 1B

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of ARID1B mRNA

NCBI chr 1:9,791,627...10,227,381
Ensembl chr 1:9,791,633...10,227,502

G

cAMP regulated phosphoprotein 21

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ARPP21 mRNA]

NCBI chr13:20,955,414...21,088,424
Ensembl chr13:20,934,846...21,088,420

G

arylsulfatase G

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of ARSG mRNA

NCBI chr12:11,751,930...11,882,844
Ensembl chr12:11,751,937...11,843,055

G

ASH2 like, histone lysine methyltransferase complex subunit

multiple interactions

Dietary Fats promotes the reaction [Resveratrol results in decreased expression of ASH2L mRNA]

NCBI chr15:48,386,426...48,417,560
Ensembl chr15:48,386,425...48,417,547

G

asparagine synthetase (glutamine-hydrolyzing)

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ASNS mRNA]

NCBI chr 9:77,318,341...77,336,290
Ensembl chr 9:77,318,213...77,343,035

G

ATPase H+ transporting V1 subunit G2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of ATP6V1G2 mRNA

NCBI chr 7:23,670,970...23,673,860
Ensembl chr 7:23,670,965...23,673,837

G

BCL2 associated X, apoptosis regulator

increases expression

Resveratrol results in increased expression of BAX protein

NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140

G

butyrylcholinesterase

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of BCHE mRNA

NCBI chr13:104,946,732...105,007,568

G

brain expressed, X-linked 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of BEX2 mRNA]

NCBI chr X:84,223,041...84,224,583
Ensembl chr X:84,222,959...84,224,613

G

brain expressed X-linked 3

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of BEX3 mRNA]

NCBI chr X:84,300,645...84,302,124
Ensembl chr X:84,300,645...84,302,119

G

brain expressed X-linked 4

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of BEX4 mRNA]

NCBI chr X:84,147,133...84,148,680
Ensembl chr X:84,147,183...84,149,084

G

caldesmon 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CALD1 mRNA

NCBI chr18:14,267,955...14,486,641
Ensembl chr18:14,267,959...14,486,726

G

calcyphosine like

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CAPSL mRNA

NCBI chr16:21,349,279...21,356,670
Ensembl chr16:21,345,366...21,356,670

G

caspase 3

increases cleavage

Resveratrol results in increased cleavage of CASP3 protein

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

catalase

multiple interactions

Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of CAT mRNA]

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

caveolae associated protein 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CAVIN2 mRNA

NCBI chr15:96,476,675...96,490,231
Ensembl chr15:96,474,284...96,490,016

G

coiled-coil domain containing 88A

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of CCDC88A mRNA]

NCBI chr 3:85,811,043...85,971,162
Ensembl chr 3:85,811,127...85,941,864

G

chemokine (C-C motif) ligand 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of CCL2 mRNA]

NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026

G

chemokine (C-C motif) ligand 8

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CCL8 mRNA

NCBI chr12:40,740,468...40,741,970
Ensembl chr12:40,740,023...40,742,022

G

C-C motif chemokine receptor 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CCR2 mRNA

NCBI chr13:29,368,735...29,374,564
Ensembl chr13:29,285,012...29,376,343

G

C-C motif chemokine receptor 9

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CCR9 mRNA

NCBI chr13:29,033,609...29,051,227
Ensembl chr13:29,033,570...29,054,598

G

CD28 molecule

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CD28 mRNA

NCBI chr15:107,128,103...107,155,431
Ensembl chr15:107,128,203...107,162,935

G

CDC42 binding protein kinase alpha

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CDC42BPA mRNA

NCBI chr10:14,649,278...14,940,988
Ensembl chr10:14,652,855...14,940,825

G

cell division cycle associated 7

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CDCA7 mRNA

NCBI chr15:79,406,837...79,447,571
Ensembl chr15:79,432,667...79,447,568

G

cyclin dependent kinase 6

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of CDK6 mRNA]

NCBI chr 9:72,510,858...72,765,631
Ensembl chr 9:72,518,101...72,764,129

G

CDK5 regulatory subunit associated protein 1 like 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CDKAL1 mRNA

NCBI chr 7:15,910,645...16,569,643
Ensembl chr 7:15,910,666...16,626,276

G

CCAAT enhancer binding protein delta

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CEBPD mRNA

NCBI chr 4:79,872,863...79,874,481
Ensembl chr 4:79,872,939...79,874,477

G

centromere protein E

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CENPE mRNA

NCBI chr 8:117,888,968...117,965,325
Ensembl chr 8:117,888,970...117,965,252

G

centromere protein F

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of CENPF mRNA]

NCBI chr 9:128,948,386...129,012,241
Ensembl chr 9:128,948,498...129,012,218

G

carboxylesterase 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CES3 mRNA

NCBI chr 6:27,627,712...27,637,827
Ensembl chr 6:27,627,742...27,638,760

G

CF transmembrane conductance regulator

increases activity

Resveratrol results in increased activity of CFTR protein

NCBI chr18:28,627,717...28,818,209
Ensembl chr18:28,627,728...28,817,950

G

chitinase 3 like 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CHI3L1 mRNA

NCBI chr 9:113,885,541...113,895,033
Ensembl chr 9:113,885,542...113,895,131

G

CAP-Gly domain containing linker protein 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CLIP1 mRNA

NCBI chr14:30,320,870...30,467,095
Ensembl chr14:30,320,958...30,467,657

G

clusterin

multiple interactions

Resveratrol promotes the reaction [Dietary Fats results in increased expression of CLU mRNA]

NCBI chr14:11,336,585...11,352,569
Ensembl chr14:11,336,595...11,349,764

G

collagen type XIV alpha 1 chain

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of COL14A1 mRNA

NCBI chr 4:18,690,197...18,925,111
Ensembl chr 4:18,690,198...18,924,971

G

collagen type I alpha 1 chain

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of COL1A1 mRNA]

NCBI chr12:26,379,087...26,397,180
Ensembl chr12:26,379,090...26,397,004

G

collagen type I alpha 2 chain

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of COL1A2 mRNA]

NCBI chr 9:74,174,484...74,210,407
Ensembl chr 9:74,173,931...74,210,397

G

collagen type III alpha 1 chain

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of COL3A1 mRNA]

NCBI chr15:93,556,914...93,595,678
Ensembl chr15:93,526,603...93,596,363

G

cytochrome c oxidase copper chaperone COX11

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of COX11 mRNA

NCBI chr12:31,268,397...31,277,850
Ensembl chr12:31,267,520...31,277,429

G

cysteine rich secretory protein LCCL domain containing 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CRISPLD2 mRNA

NCBI chr 6:3,881,715...3,944,592
Ensembl chr 6:3,881,725...3,944,583

G

C-reactive protein, pentraxin-related

decreases expression

Resveratrol results in decreased expression of CRP protein

NCBI chr 4:90,793,361...90,801,020
Ensembl chr 4:90,793,350...90,805,218

G

crystallin beta A1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CRYBA1 mRNA

NCBI chr12:45,466,051...45,473,110
Ensembl chr12:45,466,520...45,473,092

G

catenin alpha 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of CTNNA1 mRNA

NCBI chr 2:140,682,776...140,869,828
Ensembl chr 2:140,682,371...140,871,334

G

cathepsin V

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of CTSV mRNA]

NCBI chr10:25,202,360...25,208,058
Ensembl chr10:25,202,389...25,209,210

G

cytochrome b561

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of CYB561 mRNA

NCBI chr12:15,435,973...15,447,104
Ensembl chr12:15,436,803...15,447,100

G

dishevelled binding antagonist of beta catenin 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of DACT1 mRNA]

NCBI chr 1:187,719,391...187,729,568
Ensembl chr 1:187,719,290...187,729,422

G

aspartyl-tRNA synthetase 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of DARS1 mRNA

NCBI chr15:15,810,497...15,885,706
Ensembl chr15:15,810,618...15,885,706

G

decorin

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of DCN mRNA]

NCBI chr 5:91,678,601...91,713,925
Ensembl chr 5:91,682,658...91,714,235

G

DEAD-box helicase 17

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of DDX17 mRNA; Resveratrol promotes the reaction [Dietary Fats results in decreased expression of DDX17 mRNA]

NCBI chr 5:9,485,792...9,505,157
Ensembl chr 5:9,485,702...9,505,157

G

Dmx like 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of DMXL2 mRNA]

NCBI chr 1:120,138,249...120,298,603
Ensembl chr 1:120,138,336...120,298,586

G

DnaJ heat shock protein family (Hsp40) member B14

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of DNAJB14 mRNA

NCBI chr 8:120,567,395...120,623,518
Ensembl chr 8:120,567,390...120,623,513

G

destrin, actin depolymerizing factor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of DSTN mRNA

NCBI chr17:25,998,830...26,050,354
Ensembl chr17:26,043,079...26,050,353

G

dynein cytoplasmic 2 heavy chain 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of DYNC2H1 mRNA

NCBI chr 9:33,720,920...34,039,954
Ensembl chr 9:33,720,877...34,040,188

G

epithelial cell transforming 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ECT2 mRNA]

NCBI chr13:111,248,215...111,310,746
Ensembl chr13:111,248,131...111,314,828

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of EEF1A1 mRNA]

NCBI chr 1:92,421,235...92,425,053
Ensembl chr 1:92,421,230...92,425,044

G

early growth response 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of EGR1 mRNA]

NCBI chr 2:140,440,829...140,445,302
Ensembl chr 2:140,441,421...140,445,296

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ENPP1 mRNA]

NCBI chr 1:31,724,290...31,796,594
Ensembl chr 1:31,722,721...31,796,595

G

ectonucleoside triphosphate diphosphohydrolase 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of ENTPD1 mRNA

NCBI chr14:107,263,546...107,390,923
Ensembl chr14:107,263,449...107,389,010

G

epithelial cell adhesion molecule

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of EPCAM mRNA]

NCBI chr 3:93,169,800...93,185,221
Ensembl chr 3:93,168,852...93,185,653

G

ERBB receptor feedback inhibitor 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of ERRFI1 mRNA

NCBI chr 6:68,667,651...68,682,629
Ensembl chr 6:68,669,153...68,682,623

G

ETS variant transcription factor 5

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of ETV5 mRNA

NCBI chr13:123,873,346...123,930,292
Ensembl chr13:123,873,350...123,930,200

G

EYA transcriptional coactivator and phosphatase 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of EYA3 mRNA

NCBI chr 6:85,095,409...85,185,856
Ensembl chr 6:85,095,409...85,185,799

G

fatty acid binding protein 4

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA]

NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,896

G

fatty acid binding protein 6

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of FABP6 mRNA]

NCBI chr16:63,297,594...63,303,675
Ensembl chr16:63,297,595...63,303,697

G

family with sequence similarity 72 member A

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of FAM72A mRNA

NCBI chr 9:66,824,251...66,839,780

G

fibrillin 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of FBN1 mRNA]

NCBI chr 1:123,102,011...123,359,649
Ensembl chr 1:123,102,009...123,359,649

G

F-box protein 5

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of FBXO5 mRNA

NCBI chr 1:13,466,961...13,478,496
Ensembl chr 1:13,467,501...13,505,928

G

Fc epsilon receptor Ia

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of FCER1A mRNA

NCBI chr 4:91,118,867...91,125,448
Ensembl chr 4:91,118,879...91,125,437

G

forkhead box O1

decreases expression

Resveratrol results in decreased expression of FOXO1 mRNA

NCBI chr11:15,317,222...15,410,059
Ensembl chr11:15,317,124...15,410,473

G

follistatin like 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of FSTL1 mRNA]

NCBI chr13:139,847,246...139,901,972
Ensembl chr13:139,847,438...139,901,965

G

growth arrest specific 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of GAS1 mRNA]

NCBI chr10:28,509,168...28,511,554
Ensembl chr10:28,509,261...28,510,301

G

GATA binding protein 3

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of GATA3 mRNA]

NCBI chr10:63,367,684...63,397,977
Ensembl chr10:63,367,663...63,388,859

G

gap junction protein alpha 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of GJA1 mRNA]

NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156

G

gap junction protein alpha 10

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of GJA10 mRNA

NCBI chr 1:57,879,740...57,881,395
Ensembl chr 1:57,868,387...57,893,687

G

golgi integral membrane protein 4

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of GOLIM4 mRNA; Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of GOLIM4 mRNA]

NCBI chr13:106,814,825...106,895,209
Ensembl chr13:106,814,821...106,895,186

G

glycerol-3-phosphate dehydrogenase 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of GPD2 mRNA

NCBI chr15:63,592,723...63,728,636
Ensembl chr15:63,619,762...63,728,633

G

H2A.X variant histone

multiple interactions

Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of H2AX protein]

NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084

G

heparin binding EGF like growth factor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of DTR mRNA

NCBI chr 2:142,102,455...142,115,192
Ensembl chr 2:142,102,458...142,115,174

G

heterogeneous nuclear ribonucleoprotein L like

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of HNRNPLL mRNA]

NCBI chr 3:101,753,330...101,795,356
Ensembl chr 3:101,753,292...101,802,062

G

hydroxysteroid 17-beta dehydrogenase 12

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of HSD17B12 mRNA]

NCBI chr 2:18,461,487...18,611,761
Ensembl chr 2:18,456,019...18,611,782

G

heat shock protein family A (Hsp70) member 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of HSPA2 mRNA

NCBI chr 7:88,607,140...88,609,947

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of IDH2 mRNA

NCBI chr 7:55,654,298...55,675,571
Ensembl chr 7:55,651,609...55,675,554

G

insulin like growth factor binding protein 5

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of IGFBP5 mRNA

NCBI chr15:118,861,816...118,877,787
Ensembl chr15:118,857,625...118,878,120

G

inhibin subunit beta A

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of INHBA mRNA]

NCBI chr12:53,115,379...53,117,128
NCBI chr18:52,889,684...52,909,260
Ensembl chr18:52,889,684...52,900,967

G

interaction protein for cytohesin exchange factors 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of IPCEF1 mRNA

NCBI chr 1:12,511,612...12,602,736
Ensembl chr 1:12,506,220...12,602,724

G

insulin receptor substrate 1

increases expression

Resveratrol results in increased expression of IRS1 protein

PMID:21575630 PMID:21739664

NCBI chr15:128,245,846...128,307,321
Ensembl chr15:128,245,846...128,307,284

G

integrin subunit alpha 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of ITGA2 mRNA]

NCBI chr16:32,336,240...32,440,311
Ensembl chr16:32,336,292...32,437,103

G

integrin subunit alpha V

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ITGAV mRNA]

NCBI chr15:91,604,666...91,711,843
Ensembl chr15:91,604,676...91,711,851

G

potassium voltage-gated channel subfamily H member 8

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of KCNH8 mRNA]

NCBI chr13:6,104,382...6,533,505
Ensembl chr13:6,104,537...6,532,592

G

kinesin family member 11

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of KIF11 mRNA]

NCBI chr14:104,125,839...104,177,381
Ensembl chr14:104,125,898...104,177,379

G

kinesin family member 15

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of KIF15 mRNA]

NCBI chr13:27,966,586...28,041,121
Ensembl chr13:27,966,586...28,041,451

G

kinesin family member 7

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of KIF7 mRNA

NCBI chr 7:55,200,591...55,220,237
Ensembl chr 7:55,200,594...55,220,240

G

kynurenine 3-monooxygenase

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of KMO mRNA]

NCBI chr10:12,442,877...12,489,417
Ensembl chr10:12,434,769...12,490,409

G

LIF interleukin 6 family cytokine

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of LIF mRNA]

NCBI chr14:47,221,540...47,239,513
Ensembl chr14:47,221,560...47,238,749

G

lunapark, ER junction formation factor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of LNPK mRNA

NCBI chr15:81,721,637...81,805,706
Ensembl chr15:81,721,644...81,805,680

G

phosphatidylinositol 3-kinase regulatory subunit gamma

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of PIK3R3 mRNA

NCBI chr 6:165,268,260...165,402,668
Ensembl chr 6:165,268,568...165,402,649

G

uncharacterized LOC102158035

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of TRAC mRNA]

NCBI chr 7:76,471,215...77,056,010

G

lipoprotein lipase

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of LPL mRNA]

NCBI chr14:4,104,761...4,134,964
Ensembl chr14:4,104,772...4,135,814

G

limbic system associated membrane protein

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of LSAMP mRNA]

NCBI chr13:143,675,521...144,304,186
Ensembl chr13:143,675,575...144,304,151

G

MAM domain containing 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of MAMDC2 mRNA

NCBI chr 1:223,541,491...223,547,723
Ensembl chr 1:223,384,827...223,548,420

G

mitogen-activated protein kinase 1

multiple interactions

Resveratrol results in decreased phosphorylation of and results in decreased activity of MAPK1 protein

NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513

G

mitogen-activated protein kinase 3

multiple interactions

Resveratrol results in decreased phosphorylation of and results in decreased activity of MAPK3 protein

NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567

G

mitogen-activated protein kinase 8

multiple interactions

Resveratrol results in decreased phosphorylation of and results in decreased activity of MAPK8 protein

NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874

G

MARCKS like 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of MARCKSL1 mRNA

NCBI chr 6:88,785,412...88,787,772
Ensembl chr 6:88,786,175...88,787,766

G

membrane bound transcription factor peptidase, site 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of MBTPS1 mRNA

NCBI chr 6:4,503,530...4,558,601
Ensembl chr 6:4,503,565...4,558,609

G

mesenteric estrogen dependent adipogenesis

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MEDAG mRNA]

NCBI chr11:7,545,400...7,562,741
Ensembl chr11:7,545,494...7,562,737

G

microfibril associated protein 5

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of MFAP5 mRNA

NCBI chr 5:62,742,520...62,757,522
Ensembl chr 5:62,742,319...62,757,519

G

monocyte to macrophage differentiation associated 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MMD2 mRNA]

NCBI chr 3:3,728,126...3,782,605
Ensembl chr 3:3,729,531...3,775,205

G

matrix metallopeptidase 13

decreases expression
decreases activity

Resveratrol results in decreased expression of MMP13 mRNA
Resveratrol results in decreased activity of MMP13 protein

NCBI chr 9:33,549,003...33,616,700
Ensembl chr 9:33,549,008...33,561,162

G

matrix metallopeptidase 2

multiple interactions

Resveratrol inhibits the reaction [Tobacco Smoke Pollution results in increased activity of MMP2 protein]

NCBI chr 6:30,059,247...30,087,031
Ensembl chr 6:30,058,595...30,086,982

G

myelin protein zero like 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MPZL2 mRNA]

NCBI chr 9:45,566,365...45,578,168
Ensembl chr 9:45,565,513...45,578,185

G

musashi RNA binding protein 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MSI2 mRNA]

NCBI chr12:33,537,163...33,974,845
Ensembl chr12:33,537,196...33,975,548

G

mechanistic target of rapamycin kinase

increases expression

Resveratrol results in increased expression of MTOR protein

NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MYCN mRNA]

NCBI chr 3:121,543,201...121,549,678
Ensembl chr 3:121,543,109...121,549,046

G

myosin heavy chain 10

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MYH10 mRNA]

NCBI chr12:53,647,579...53,781,552

G

myosin light chain kinase

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of MYLK mRNA

NCBI chr13:136,509,878...136,809,674
Ensembl chr13:136,509,755...136,809,668

G

myosin X

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of MYO10 mRNA

NCBI chr16:5,907,111...6,145,485
Ensembl chr16:5,907,116...6,094,845

G

neurobeachin

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of NBEA mRNA

NCBI chr11:11,085,081...11,722,859
Ensembl chr11:11,084,992...11,722,847

G

NDC80 kinetochore complex component

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of NDC80 mRNA]

NCBI chr 6:104,000,794...104,055,785
Ensembl chr 6:103,999,034...104,055,760

G

NIMA related kinase 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of NEK2 mRNA

NCBI chr 9:131,547,044...131,560,527
Ensembl chr 9:131,547,069...131,561,095

G

NFKB inhibitor alpha

decreases degradation

Resveratrol results in decreased degradation of NFKBIA protein

NCBI chr 7:64,508,119...64,510,754
Ensembl chr 7:64,507,822...64,511,277

G

nitric oxide synthase 2

decreases expression
multiple interactions

Resveratrol results in decreased expression of NOS2 protein
Resveratrol inhibits the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]

NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146

G

protegrin 4

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of CAMP mRNA]

NCBI chr13:30,932,411...30,934,626
Ensembl chr13:30,932,232...30,987,873

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of NQO1 mRNA

NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590

G

neuronal regeneration related protein

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of NREP mRNA]

NCBI chr 2:117,505,851...117,867,805
Ensembl chr 2:117,838,660...117,867,801

G

NUF2 component of NDC80 kinetochore complex

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of NUF2 mRNA]

NCBI chr 4:87,162,873...87,194,193
Ensembl chr 4:87,162,818...87,194,170

G

nucleolar and spindle associated protein 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of NUSAP1 mRNA]

NCBI chr 1:129,992,797...130,065,641
Ensembl chr 1:129,992,804...130,065,605

G

purinergic receptor P2Y12

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of P2RY12 mRNA

NCBI chr13:91,522,754...91,572,195
Ensembl chr13:91,521,817...91,572,005

G

p21 (RAC1) activated kinase 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PAK3 mRNA

NCBI chr X:90,941,976...91,244,331
Ensembl chr X:90,942,077...91,238,565

G

PALM2-AKAP2 fusion

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PALM2AKAP2 mRNA]

NCBI chr 1:250,824,055...250,968,545
NCBI chr 1:250,984,658...251,190,244
Ensembl chr 1:250,680,942...251,190,244

G

3'-phosphoadenosine 5'-phosphosulfate synthase 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PAPSS1 mRNA

NCBI chr 8:114,252,059...114,369,309
Ensembl chr 8:114,252,416...114,373,427

G

parvin beta

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of PARVB mRNA]

NCBI chr 5:4,906,667...5,015,494
Ensembl chr 5:4,906,685...5,015,441

G

PDZ binding kinase

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PBK mRNA]

NCBI chr14:11,543,657...11,577,286
Ensembl chr14:11,543,603...11,566,702

G

PCNA clamp associated factor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of PCLAF mRNA

NCBI chr 1:107,659,509...107,669,477
Ensembl chr 1:107,659,509...107,670,954

G

phosphodiesterase 4D

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PDE4D mRNA

NCBI chr16:37,897,300...39,406,534
Ensembl chr16:37,897,302...39,306,364

G

PDZ domain containing 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PDZD2 mRNA]

NCBI chr16:17,940,113...18,355,540

G

paternally expressed 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PEG3 mRNA

NCBI chr 6:61,281,931...61,307,788
Ensembl chr 6:61,285,456...61,292,885

G

phosphotyrosine interaction domain containing 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PID1 mRNA

NCBI chr15:130,080,821...130,215,548
Ensembl chr15:130,075,143...130,332,698

G

piwi like RNA-mediated gene silencing 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of PIWIL3 mRNA

NCBI chr14:42,834,819...42,869,486
Ensembl chr14:42,835,302...42,869,566

G

polo like kinase 4

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PLK4 mRNA]

NCBI chr 8:96,989,011...97,013,324
Ensembl chr 8:96,991,847...97,013,461

G

peroxisome proliferator activated receptor alpha

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]

NCBI chr 5:3,302,755...3,321,091
Ensembl chr 5:3,300,741...3,364,239

G

peroxisome proliferator activated receptor gamma

decreases expression
multiple interactions

Resveratrol results in decreased expression of PPARG mRNA; Resveratrol results in decreased expression of PPARG protein
Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of PPARG protein]

PMID:17851734 PMID:21575630 PMID:21739664

NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944

G

PPARG coactivator 1 alpha

increases expression

Resveratrol results in increased expression of PPARGC1A protein

NCBI chr 8:17,841,844...18,527,953
Ensembl chr 8:17,841,844...17,946,992

G

phosphoribosyl pyrophosphate amidotransferase

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PPAT mRNA]

NCBI chr 8:55,652,194...55,701,077
Ensembl chr 8:55,654,377...55,701,077

G

pro-platelet basic protein

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PPBP mRNA

NCBI chr 8:70,021,468...70,022,490
Ensembl chr 8:70,021,439...70,023,964

G

protein phosphatase 1 regulatory subunit 3B

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PPP1R3B mRNA

NCBI chr15:56,002,383...56,013,477
Ensembl chr15:56,002,378...56,013,478

G

protein S

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of PROS1 mRNA

NCBI chr13:165,915,298...165,999,118
Ensembl chr13:165,911,366...165,999,811

G

serine protease 16

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PRSS16 mRNA]

NCBI chr 7:21,276,997...21,285,314
Ensembl chr 7:21,276,965...21,285,311

G

phosphoserine aminotransferase 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PSAT1 mRNA]

NCBI chr 1:231,142,673...231,172,364
Ensembl chr 1:231,142,625...231,172,360

G

patched domain containing 4

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of PTCHD4 mRNA

NCBI chr 7:42,570,100...42,770,035
Ensembl chr 7:42,570,094...42,770,225

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression

[Dietary Fats co-treated with Resveratrol] results in decreased expression of PTGS2 mRNA; Resveratrol inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]
Resveratrol results in decreased expression of PTGS2 protein

PMID:20825639 PMID:21852083

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

protein tyrosine phosphatase receptor type R

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of PTPRR mRNA]

NCBI chr 5:34,794,970...35,048,550
Ensembl chr 5:34,794,977...35,047,818

G

RAB27B, member RAS oncogene family

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of RAB27B mRNA

NCBI chr 1:104,241,500...104,418,721
Ensembl chr 1:104,241,571...104,417,084

G

RAB38, member RAS oncogene family

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of RAB38 mRNA

NCBI chr 9:21,577,083...21,640,637
Ensembl chr 9:21,577,033...21,640,115

G

retinoic acid receptor responder 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of RARRES1 mRNA

NCBI chr13:98,461,307...98,506,552
Ensembl chr13:98,461,320...98,506,173

G

retinol binding protein 4

decreases expression
multiple interactions

Resveratrol results in decreased expression of RBP4 protein
Resveratrol inhibits the reaction [Dietary Fats results in increased expression of RBP4 protein]

PMID:21575630 PMID:21739664

NCBI chr14:105,037,360...105,044,552
Ensembl chr14:105,037,464...105,044,765

G

regulator of calcineurin 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of RCAN1 mRNA

NCBI chr13:198,106,256...198,205,727
Ensembl chr13:198,102,098...198,205,629

G

receptor accessory protein 5

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of REEP5 mRNA

NCBI chr 2:116,845,681...116,886,361
Ensembl chr 2:116,845,571...116,886,358

G

ras homolog family member U

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of RHOU mRNA

NCBI chr14:60,667,104...60,677,582
Ensembl chr14:60,667,108...60,677,731

G

RHO family interacting cell polarization regulator 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of RIPOR2 mRNA

NCBI chr 7:19,609,358...19,842,345
Ensembl chr 7:19,609,358...19,838,093

G

ring finger protein 113A

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of RNF113A mRNA]

NCBI chr X:98,218,689...98,219,931
Ensembl chr X:98,218,565...98,219,773

G

ring finger protein 128

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of RNF128 mRNA]

NCBI chr X:87,111,875...87,211,605
Ensembl chr X:87,111,870...87,211,601

G

ribosomal protein L17

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of RPL17 mRNA

NCBI chr 1:99,044,511...99,048,406
Ensembl chr 1:99,043,219...99,048,410

G

ribosomal protein L32

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of RPL32 mRNA

NCBI chr13:68,788,109...68,793,265
Ensembl chr13:68,786,856...68,793,204

G

ribosomal protein L6

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of RPL6 mRNA

NCBI chr14:39,302,447...39,309,239
Ensembl chr14:39,303,350...39,309,236

G

SET binding factor 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SBF2 mRNA

NCBI chr 2:49,242,739...49,691,807
Ensembl chr 2:49,242,734...49,698,478

G

Scm polycomb group protein like 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SCML2 mRNA

NCBI chr X:14,715,357...14,823,016
Ensembl chr X:14,717,606...14,823,413

G

serine carboxypeptidase 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SCPEP1 mRNA

NCBI chr12:33,265,509...33,296,805
Ensembl chr12:33,265,562...33,298,142

G

serine dehydratase

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SDS mRNA

NCBI chr14:38,503,922...38,513,908
Ensembl chr14:38,503,933...38,513,878

G

selectin P

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SELP mRNA

NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,399,955

G

serpin family B member 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SERPINB2 mRNA

NCBI chr 1:157,871,919...157,886,525
Ensembl chr 1:157,872,212...157,886,602

G

serpin family E member 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SERPINE1 mRNA

NCBI chr 3:8,863,738...8,871,572
Ensembl chr 3:8,863,695...8,871,547

G

splicing factor 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SF1 mRNA

NCBI chr 2:7,391,295...7,404,693
Ensembl chr 2:7,391,383...7,404,948

G

SH3 domain binding glutamate rich protein like

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SH3BGRL mRNA

NCBI chr X:64,617,350...64,709,006

G

SH3 domain binding glutamate rich protein like 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SH3BGRL2 mRNA

NCBI chr 1:86,416,281...86,481,805
Ensembl chr 1:86,358,483...86,481,776

G

shieldin complex subunit 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SHLD2 mRNA

NCBI chr14:88,005,599...88,121,155
Ensembl chr14:88,005,611...88,121,352

G

serine hydroxymethyltransferase 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of SHMT1 mRNA]

NCBI chr12:60,414,421...60,435,451
Ensembl chr12:60,416,463...60,435,450

G

sirtuin 1

increases expression
multiple interactions

Resveratrol results in increased expression of SIRT1 mRNA; Resveratrol results in increased expression of SIRT1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]]; Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SIRT1 protein]

PMID:17037214 PMID:17851734 PMID:23065251 PMID:36549457

NCBI chr14:71,091,167...71,126,351
Ensembl chr14:71,091,167...71,123,297

G

MHC class I antigen 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of HLA-A mRNA

NCBI chr 7:22,916,747...22,959,405

G

MHC class I antigen 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of HLA-B mRNA; Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of HLA-B mRNA]

NCBI chr 7:22,938,211...22,942,735

G

solute carrier family 20 member 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SLC20A1 mRNA

NCBI chr 3:43,844,716...43,860,547
Ensembl chr 3:43,844,722...43,860,547

G

solute carrier family 24 member 5

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of SLC24A5 mRNA]

NCBI chr 1:123,635,077...123,657,205
Ensembl chr 1:123,635,043...123,656,736

G

solute carrier family 2 member 1

increases expression

Resveratrol results in increased expression of SLC2A1 protein

NCBI chr 6:168,535,398...168,561,170
Ensembl chr 6:168,535,440...168,560,867

G

solute carrier family 2 member 4

increases expression
multiple interactions

Resveratrol results in increased expression of SLC2A4 protein
Resveratrol inhibits the reaction [Dietary Fats results in decreased expression of SLC2A4 protein]

PMID:21575630 PMID:21739664

NCBI chr12:52,628,746...52,634,965
Ensembl chr12:52,628,450...52,634,967

G

solute carrier family 40 member 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SLC40A1 mRNA

NCBI chr15:94,140,635...94,161,793
Ensembl chr15:94,141,988...94,167,408

G

solute carrier family 4 member 4

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of SLC4A4 mRNA]

NCBI chr 8:67,768,955...68,177,213
Ensembl chr 8:67,706,874...68,177,212

G

superoxide dismutase 1

multiple interactions

Resveratrol inhibits the reaction [Lipopolysaccharides results in decreased expression of SOD1 mRNA]

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

SRY-box transcription factor 13

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SOX13 mRNA

NCBI chr 9:64,745,762...64,780,942
Ensembl chr 9:64,731,969...64,780,942

G

SRY-box transcription factor 4

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SOX4 mRNA

NCBI chr 7:16,886,834...16,895,488
Ensembl chr 7:16,891,319...16,892,752

G

secreted protein acidic and cysteine rich

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of SPARC mRNA]

NCBI chr16:71,368,164...71,380,972
Ensembl chr16:71,357,586...71,381,161

G

SPC25 component of NDC80 kinetochore complex

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SPC25 mRNA

NCBI chr15:75,339,171...75,371,275
Ensembl chr15:75,336,514...75,371,277

G

spen family transcriptional repressor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SPEN mRNA

NCBI chr 6:75,015,565...75,107,468
Ensembl chr 6:75,015,521...75,107,033

G

secreted phosphoprotein 1

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of SPP1 mRNA

NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340

G

SSX family member 2 interacting protein

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SSX2IP mRNA

NCBI chr 6:129,049,186...129,113,622
Ensembl chr 6:129,055,523...129,114,217

G

syntaxin 8

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of STX8 mRNA]

NCBI chr12:54,296,988...54,544,668
Ensembl chr12:54,296,995...54,544,646

G

synaptotagmin like 4

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of SYTL4 mRNA

NCBI chr X:82,367,546...82,437,439
Ensembl chr X:82,367,549...82,437,401

G

transgelin 2

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of TAGLN2 mRNA]

NCBI chr 4:90,566,272...90,574,762

G

tissue factor pathway inhibitor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of TFPI mRNA

NCBI chr15:92,345,083...92,409,962
Ensembl chr15:92,345,075...92,409,905

G

transforming growth factor beta 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of TGFB2 mRNA

NCBI chr10:8,306,136...8,435,307
Ensembl chr10:8,305,539...8,390,341

G

thyroid hormone receptor associated protein 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of THRAP3 mRNA

NCBI chr 6:92,350,021...92,412,335
Ensembl chr 6:92,355,667...92,412,330

G

TIMP metallopeptidase inhibitor 3

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of TIMP3 mRNA]

NCBI chr 5:12,185,816...12,242,599
Ensembl chr 5:12,185,818...12,242,581

G

transmembrane p24 trafficking protein 4

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of TMED4 mRNA

NCBI chr18:50,698,819...50,702,333
Ensembl chr18:50,699,470...50,702,705

G

transmembrane protein 117

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of TMEM117 mRNA

NCBI chr 5:74,917,081...75,402,839
Ensembl chr 5:74,917,463...75,406,367

G

transmembrane protein 40

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of TMEM40 mRNA

NCBI chr13:68,705,606...68,737,194
Ensembl chr13:68,692,120...68,758,651

G

transmembrane protein 47

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of TMEM47 mRNA

NCBI chr X:30,584,044...30,615,233
Ensembl chr X:30,584,046...30,615,232

G

thymosin beta 10

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of TMSB10 mRNA

NCBI chr 3:59,776,236...59,777,252
Ensembl chr 3:59,776,236...59,777,252

G

thymosin beta 4 X-linked

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of TMSB4Y mRNA

NCBI chr X:9,649,516...9,651,662
Ensembl chr X:9,650,179...9,651,661

G

DNA topoisomerase II alpha

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of TOP2A mRNA

NCBI chr12:22,001,300...22,028,452
Ensembl chr12:22,001,282...22,028,450

G

tumor protein p53

multiple interactions

Resveratrol results in increased expression of and results in increased acetylation of TP53 protein

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

TPX2 microtubule nucleation factor

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of TPX2 mRNA

NCBI chr17:35,431,271...35,484,814
Ensembl chr17:35,431,395...35,485,065

G

tripartite motif containing 13

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of TRIM13 mRNA]

NCBI chr11:17,785,031...17,850,005
Ensembl chr11:17,793,784...17,849,732

G

TSC22 domain family member 2

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of TSC22D2 mRNA

NCBI chr13:90,640,490...90,697,671
Ensembl chr13:90,641,175...90,691,568

G

ubiquitin conjugating enzyme E2 C

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of UBE2C mRNA

NCBI chr17:48,018,403...48,021,542
Ensembl chr17:48,018,400...48,021,534

G

ubiquitin conjugating enzyme E2 U

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of UBE2U mRNA

NCBI chr 6:148,233,498...148,314,193
Ensembl chr 6:148,233,412...148,305,330

G

UDP-glucuronosyltransferase 2B31

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of UGT2B11 mRNA

NCBI chr 8:66,310,697...66,323,755
Ensembl chr 8:66,308,581...66,324,051

G

ubiquitin like with PHD and ring finger domains 1

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of UHRF1 mRNA]

NCBI chr 2:73,898,061...73,937,727
Ensembl chr 2:73,898,071...73,931,769

G

usherin

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in increased expression of USH2A mRNA

NCBI chr10:5,825,591...6,662,733

G

vav guanine nucleotide exchange factor 3

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of VAV3 mRNA

NCBI chr 4:111,825,071...112,202,833
Ensembl chr 4:111,824,896...112,202,825

G

WEE1 G2 checkpoint kinase

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of WEE1 mRNA

NCBI chr 2:49,880,416...49,894,509
Ensembl chr 2:49,880,435...49,894,499

G

zinc finger DHHC-type palmitoyltransferase 2

multiple interactions

Resveratrol promotes the reaction [Dietary Fats results in increased expression of ZDHHC2 mRNA]

NCBI chr17:4,855,129...4,928,109
Ensembl chr17:4,855,345...4,928,664

G

zinc finger protein 462

multiple interactions

[Dietary Fats co-treated with Resveratrol] results in decreased expression of ZNF462 mRNA

NCBI chr 1:248,029,136...248,181,792
Ensembl chr 1:248,031,631...248,179,784

G

zinc finger protein 507

multiple interactions

Resveratrol inhibits the reaction [Dietary Fats results in increased expression of ZNF507 mRNA]

NCBI chr 6:42,274,192...42,316,764
Ensembl chr 6:42,274,206...42,316,755

zearalenone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 9

decreases expression

Zearalenone results in decreased expression of ABCC9 mRNA

NCBI chr 5:51,536,531...51,673,583
Ensembl chr 5:51,536,526...51,691,595

G

ATP binding cassette subfamily F member 1

increases expression

Zearalenone results in increased expression of ABCF1 mRNA

NCBI chr 7:23,126,255...23,144,030
Ensembl chr 7:23,126,283...23,145,006

G

actin binding LIM protein family member 2

decreases expression

Zearalenone results in decreased expression of ABLIM2 mRNA

NCBI chr 8:2,948,948...3,054,974
Ensembl chr 8:2,916,775...3,054,969

G

angiotensin converting enzyme 2

decreases expression

Zearalenone results in decreased expression of ACE2 mRNA

NCBI chr X:12,099,849...12,152,204
Ensembl chr X:12,093,242...12,151,286

G

ADAM metallopeptidase domain 22

decreases expression

Zearalenone results in decreased expression of ADAM22 mRNA

NCBI chr 9:68,253,023...68,490,327
Ensembl chr 9:68,253,065...68,487,619

G

ADAM metallopeptidase domain 33

decreases expression

Zearalenone results in decreased expression of ADAM33 mRNA

NCBI chr17:32,023,102...32,038,464
Ensembl chr17:32,023,091...32,037,880

G

ADAM metallopeptidase with thrombospondin type 1 motif 18

decreases expression

Zearalenone results in decreased expression of ADAMTS18 mRNA

NCBI chr 6:10,488,504...10,652,508
Ensembl chr 6:10,328,944...10,652,504

G

ADAM metallopeptidase with thrombospondin type 1 motif 20

increases expression

Zearalenone results in increased expression of ADAMTS20 mRNA

NCBI chr 5:74,502,098...74,672,703
Ensembl chr 5:74,503,116...74,672,733

G

ADAM metallopeptidase with thrombospondin type 1 motif 3

decreases expression

Zearalenone results in decreased expression of ADAMTS3 mRNA

NCBI chr 8:68,675,067...68,948,537
Ensembl chr 8:68,675,070...68,948,414

G

ADAMTS like 1

decreases expression

Zearalenone results in decreased expression of ADAMTSL1 mRNA

NCBI chr 1:203,936,654...204,944,236
Ensembl chr 1:203,936,657...204,942,412

G

adenylate cyclase 5

decreases expression

Zearalenone results in decreased expression of ADCY5 mRNA

NCBI chr13:136,965,746...137,133,795
Ensembl chr13:136,972,801...137,135,347

G

ADCYAP receptor type I

decreases expression

Zearalenone results in decreased expression of ADCYAP1R1 mRNA

NCBI chr18:41,915,180...41,972,327
Ensembl chr18:41,917,428...41,972,301

G

adhesion G protein-coupled receptor E5

increases expression

Zearalenone results in increased expression of ADGRE5 mRNA

NCBI chr 2:64,844,793...64,862,231
Ensembl chr 2:64,844,798...64,890,939

G

adrenoceptor alpha 2A

decreases expression

Zearalenone results in decreased expression of ADRA2A mRNA

NCBI chr14:121,469,572...121,470,924
Ensembl chr14:121,469,527...121,470,924

G

apoptosis inducing factor mitochondria associated 2

increases expression

Zearalenone results in increased expression of AIFM2 mRNA

NCBI chr14:73,054,433...73,074,605
Ensembl chr14:73,055,228...73,074,567

G

aldo-keto reductase family 1, member C1

decreases expression

Zearalenone results in decreased expression of AKR1C1 mRNA

NCBI chr10:65,580,297...65,594,998
Ensembl chr10:65,576,464...65,678,248

G

aldehyde dehydrogenase 1 family member A3

decreases expression

Zearalenone results in decreased expression of ALDH1A3 mRNA

NCBI chr 1:139,451,080...139,491,514
Ensembl chr 1:139,451,049...139,491,511

G

aldehyde dehydrogenase 3 family member A1

decreases expression

Zearalenone results in decreased expression of ALDH3A1 mRNA

NCBI chr12:59,895,476...59,905,900
Ensembl chr12:59,897,496...59,905,897

G

angiopoietin 4

decreases expression

Zearalenone results in decreased expression of ANGPT4 mRNA

NCBI chr17:34,345,926...34,394,977
Ensembl chr17:34,348,556...34,402,851

G

annexin A8

increases expression

Zearalenone results in increased expression of ANXA8 mRNA

NCBI chr14:88,319,209...88,340,716

G

apoptotic peptidase activating factor 1

decreases expression

Zearalenone results in decreased expression of APAF1 mRNA

NCBI chr 5:85,166,616...85,258,751
Ensembl chr 5:85,166,628...85,258,364

G

Rho GTPase activating protein 20

decreases expression

Zearalenone results in decreased expression of ARHGAP20 mRNA

NCBI chr 9:38,471,049...38,582,221
Ensembl chr 9:38,474,865...38,582,242

G

asporin

decreases expression

Zearalenone results in decreased expression of ASPN mRNA

NCBI chr 3:42,165,553...42,192,902
Ensembl chr 3:42,165,561...42,192,813

G

astrotactin 1

decreases expression

Zearalenone results in decreased expression of ASTN1 mRNA

NCBI chr 9:118,649,144...118,969,032
Ensembl chr 9:118,646,910...118,968,970

G

ATPase Na+/K+ transporting subunit alpha 2

decreases expression

Zearalenone results in decreased expression of ATP1A2 mRNA

NCBI chr 4:90,341,316...90,371,040
Ensembl chr 4:90,341,322...90,370,996

G

activator of transcription and developmental regulator AUTS2

decreases expression

Zearalenone results in decreased expression of AUTS2 mRNA

NCBI chr 3:13,565,439...14,794,365
Ensembl chr 3:13,565,281...14,794,365

G

vasopressin receptor 1A

decreases expression

Zearalenone results in decreased expression of AVPR1A mRNA

NCBI chr 5:27,824,991...27,832,794
Ensembl chr 5:27,824,992...27,832,703

G

BAALC binder of MAP3K1 and KLF4

increases expression

Zearalenone results in increased expression of BAALC mRNA

NCBI chr 4:33,894,240...33,983,920
Ensembl chr 4:33,892,079...33,984,121

G

BAI1 associated protein 3

decreases expression

Zearalenone results in decreased expression of BAIAP3 mRNA

NCBI chr 3:40,536,557...40,550,508
Ensembl chr 3:40,537,399...40,550,471

G

BCL2 apoptosis regulator

decreases expression
multiple interactions

Zearalenone results in decreased expression of BCL2 mRNA
[Acetylcysteine co-treated with Zearalenone co-treated with deoxynivalenol] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of BCL2 protein; [Acetylcysteine co-treated with Zearalenone] results in increased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone co-treated with deoxynivalenol] results in decreased expression of BCL2 protein; [fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in decreased expression of BCL2 mRNA]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]; fumonisin B1 inhibits the reaction [Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]; Zearalenone inhibits the reaction [fumonisin B1 inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]]; Zearalenone inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in decreased expression of BCL2 mRNA]]

NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879

G

bone morphogenetic protein 15

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of BMP15 mRNA]

NCBI chr X:44,613,122...44,620,575
Ensembl chr X:44,613,122...44,620,575

G

bone morphogenetic protein 2

affects expression

Zearalenone affects the expression of BMP2 mRNA

NCBI chr17:15,750,487...15,762,982
Ensembl chr17:15,749,835...15,761,195

G

BCL2 family apoptosis regulator BOK

increases expression

Zearalenone results in increased expression of BOK mRNA

NCBI chr15:140,171,134...140,184,126
Ensembl chr15:140,171,143...140,184,121

G

BPI fold containing family C

decreases expression

Zearalenone results in decreased expression of BPIFC mRNA

NCBI chr 5:12,526,928...12,578,958
Ensembl chr 5:12,542,266...12,578,954

G

complement C3

decreases expression

Zearalenone results in decreased expression of C3 mRNA

NCBI chr 2:72,431,470...72,471,622
Ensembl chr 2:72,431,212...72,472,228

G

chromosome 3 C16orf89 homolog

increases expression

Zearalenone results in increased expression of C3H16ORF89 mRNA

NCBI chr 3:37,346,530...37,365,367
Ensembl chr 3:37,346,532...37,365,357

G

complement C4A (Rodgers blood group)

decreases expression

Zearalenone results in decreased expression of C4A mRNA

NCBI chr 7:24,068,019...24,083,060
Ensembl chr 7:24,068,019...24,083,061

G

complement component 4 binding protein alpha

decreases expression

Zearalenone results in decreased expression of C4BPA mRNA

NCBI chr 9:67,726,159...67,774,369
Ensembl chr 9:67,731,179...67,776,115

G

carbonic anhydrase 11

decreases expression

Zearalenone results in decreased expression of CA11 mRNA

NCBI chr 6:53,993,183...53,999,357
Ensembl chr 6:53,993,394...53,999,172

G

calcium voltage-gated channel subunit alpha1 E

decreases expression

Zearalenone results in decreased expression of CACNA1E mRNA

NCBI chr 9:122,827,386...123,318,372
Ensembl chr 9:123,006,195...123,315,319

G

calcium voltage-gated channel subunit alpha1 G

decreases expression

Zearalenone results in decreased expression of CACNA1G mRNA

NCBI chr12:26,838,633...26,912,344
Ensembl chr12:26,844,079...26,912,110

G

calcium voltage-gated channel subunit alpha1 H

decreases expression

Zearalenone results in decreased expression of CACNA1H mRNA

NCBI chr 3:40,637,420...40,694,616
Ensembl chr 3:40,637,427...40,695,177

G

caspase 1, apoptosis-related cysteine peptidase

increases expression
multiple interactions

Zearalenone results in increased expression of CASP1 mRNA; Zearalenone results in increased expression of CASP1 protein
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 mRNA]

NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328

G

caspase 3

multiple interactions
increases expression

[Acetylcysteine co-treated with Zearalenone] results in decreased expression of CASP3 protein; [fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA; [fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; Acetylcysteine inhibits the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 protein]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]]; deoxynivalenol promotes the reaction [[fumonisin B1 co-treated with Zearalenone] results in increased expression of CASP3 mRNA]; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CASP3 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]]; Zearalenone promotes the reaction [[fumonisin B1 co-treated with deoxynivalenol] results in increased expression of CASP3 mRNA]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 protein]

NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213

G

catalase

increases expression

Zearalenone results in increased expression of CAT mRNA

NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452

G

coiled-coil domain containing 158

decreases expression

Zearalenone results in decreased expression of CCDC158 mRNA

NCBI chr 8:71,990,113...72,088,966
Ensembl chr 8:71,990,119...72,088,829

G

cholecystokinin B receptor

increases expression

Zearalenone results in increased expression of CCKBR mRNA

NCBI chr 9:3,409,222...3,419,513

G

chemokine (C-C motif) ligand 2

multiple interactions
increases expression

[deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of CCL2 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CCL2 mRNA
Zearalenone results in increased expression of CCL2 mRNA; Zearalenone results in increased expression of CCL2 protein

PMID:23688591 PMID:29758222

NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026

G

C-C motif chemokine ligand 20

increases expression

Zearalenone results in increased expression of CCL20 mRNA

NCBI chr15:129,172,743...129,176,069

G

C-C motif chemokine ligand 21

increases expression

Zearalenone results in increased expression of CCL21 mRNA

NCBI chr10:32,093,783...32,094,482
Ensembl chr10:32,093,763...32,096,224

G

cyclin B1

decreases expression

Zearalenone results in decreased expression of CCNB1 mRNA; Zearalenone results in decreased expression of CCNB1 protein

NCBI chr16:47,338,239...47,348,385
Ensembl chr16:47,338,110...47,348,377

G

CD209 molecule

decreases expression

Zearalenone results in decreased expression of CD209 mRNA

NCBI chr 2:71,394,414...71,397,711
Ensembl chr 2:71,394,391...71,397,968

G

CD244 molecule

increases expression

Zearalenone results in increased expression of CD244 mRNA

NCBI chr 4:89,668,221...89,700,974
Ensembl chr 4:89,668,239...89,700,972

G

cadherin 17

affects expression

Zearalenone affects the expression of CDH17 mRNA

NCBI chr 4:42,508,852...42,597,888
Ensembl chr 4:42,515,276...42,597,772

G

cyclin dependent kinase 1

decreases expression

Zearalenone results in decreased expression of CDK1 mRNA; Zearalenone results in decreased expression of CDK1 protein

NCBI chr14:64,233,945...64,255,290
Ensembl chr14:64,233,987...64,372,197

G

CMT1A duplicated region transcript 4

decreases expression

Zearalenone results in decreased expression of CDRT4 mRNA

NCBI chr12:58,816,336...58,881,611

G

complement factor properdin

decreases expression

Zearalenone results in decreased expression of ELK1 mRNA; Zearalenone results in decreased expression of ELK1 protein

NCBI chr X:42,157,980...42,174,964
Ensembl chr X:42,157,988...42,174,951

G

calcineurin like EF-hand protein 2

decreases expression

Zearalenone results in decreased expression of CHP2 mRNA

NCBI chr 3:22,473,241...22,478,697
Ensembl chr 3:22,473,247...22,478,588

G

claudin 1

decreases expression

Zearalenone results in decreased expression of CLDN1 protein

NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657

G

C-type lectin domain family 4 member G

decreases expression

Zearalenone results in decreased expression of CLEC4G mRNA

NCBI chr 2:71,433,406...71,436,570
Ensembl chr 2:71,433,421...71,436,567

G

chloride intracellular channel 3

increases expression

Zearalenone results in increased expression of CLIC3 mRNA

G

chemerin chemokine-like receptor 2

decreases expression

Zearalenone results in decreased expression of CMKLR2 mRNA

NCBI chr15:109,467,078...109,528,931
Ensembl chr15:109,467,080...109,521,100

G

contactin 4

decreases expression

Zearalenone results in decreased expression of CNTN4 mRNA

NCBI chr13:58,642,653...59,642,134
Ensembl chr13:58,974,198...59,642,130

G

collagen beta(1-O)galactosyltransferase 2

decreases expression

Zearalenone results in decreased expression of COLGALT2 mRNA

NCBI chr 9:125,149,806...125,291,092
Ensembl chr 9:125,148,753...125,291,057

G

carboxypeptidase A1

increases expression

Zearalenone results in increased expression of CPA1 mRNA

NCBI chr18:18,466,564...18,482,099
Ensembl chr18:18,469,921...18,476,327

G

C3 and PZP like alpha-2-macroglobulin domain containing 8

decreases expression

Zearalenone results in decreased expression of CPAMD8 mRNA

NCBI chr 2:60,636,025...60,742,120
Ensembl chr 2:60,636,047...60,742,137

G

cadherin like and PC-esterase domain containing 1

decreases expression

Zearalenone results in decreased expression of CPED1 mRNA

NCBI chr18:25,655,730...25,937,923
Ensembl chr18:25,655,735...25,937,232

G

C-X-C motif chemokine ligand 13

decreases expression

Zearalenone results in decreased expression of CXCL13 mRNA

NCBI chr 8:73,071,261...73,077,342

G

C-X-C motif chemokine ligand 14

increases expression

Zearalenone results in increased expression of CXCL14 mRNA

NCBI chr 2:137,803,988...137,813,118
Ensembl chr 2:137,803,992...137,813,118

G

C-X-C motif chemokine ligand 8

increases expression
decreases secretion
multiple interactions

Zearalenone results in increased expression of CXCL8 mRNA
Zearalenone results in decreased secretion of CXCL8 protein
[deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of CXCL8 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of CXCL8 mRNA

PMID:21763767 PMID:23688591 PMID:34933075

NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861

G

C-X-C motif chemokine receptor 2

increases expression

Zearalenone results in increased expression of CXCR2 mRNA; Zearalenone results in increased expression of CXCR2 protein

NCBI chr15:120,219,657...120,230,203

G

cytochrome c, somatic

increases expression
multiple interactions

Zearalenone results in increased expression of CYCS mRNA
[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]]; deoxynivalenol promotes the reaction [[Zearalenone co-treated with fumonisin B1] results in increased expression of CYCS mRNA]; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol promotes the reaction [Zearalenone results in increased expression of CYCS mRNA]]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of CYCS mRNA]

NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866

G

cytochrome P450 family 11 subfamily A member 1

multiple interactions

Zearalenone inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP11A1 mRNA]

NCBI chr 7:59,172,829...59,188,479
Ensembl chr 7:59,175,758...59,188,478

G

cytochrome P450 19A3

multiple interactions
decreases expression

Zearalenone inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP19A1 mRNA]
Zearalenone results in decreased expression of CYP19A1 protein

PMID:17656051 PMID:29758222

NCBI chr 1:120,476,890...120,556,103
Ensembl chr 1:120,367,667...120,695,899

G

cytochrome P450 family 21 subfamily A member 1

decreases expression

Zearalenone results in decreased expression of CYP21A1 mRNA

NCBI chr 7:24,086,138...24,089,364
Ensembl chr 7:24,086,218...24,089,370

G

cytochrome P450 family 4 subfamily F member 22

increases expression

Zearalenone results in increased expression of CYP4F22 mRNA

NCBI chr 2:62,078,403...62,110,891
Ensembl chr 2:62,081,269...62,110,899

G

DNA damage inducible transcript 4

increases expression

Zearalenone results in increased expression of DDIT4 mRNA

NCBI chr14:75,117,708...75,119,907
Ensembl chr14:75,117,710...75,119,902

G

defensin beta 1

increases expression

Zearalenone results in increased expression of DEFB1 mRNA

G

delta 4-desaturase, sphingolipid 2

increases expression

Zearalenone results in increased expression of DEGS2 mRNA

NCBI chr 7:121,058,102...121,131,612
Ensembl chr 7:121,058,105...121,076,328

G

dickkopf WNT signaling pathway inhibitor 1

decreases expression

Zearalenone results in decreased expression of DKK1 mRNA

NCBI chr14:97,487,854...97,490,118
Ensembl chr14:97,487,226...97,490,288

G

discs large MAGUK scaffold protein 2

decreases expression

Zearalenone results in decreased expression of DLG2 mRNA

NCBI chr 9:17,575,991...19,547,417
Ensembl chr 9:17,576,135...19,545,916

G

discs large MAGUK scaffold protein 4

decreases expression

Zearalenone results in decreased expression of DLG4 mRNA

NCBI chr12:52,550,138...52,574,021
Ensembl chr12:52,550,141...52,575,143

G

delta like non-canonical Notch ligand 1

increases expression

Zearalenone results in increased expression of DLK1 mRNA

NCBI chr 7:121,565,844...121,577,493
Ensembl chr 7:121,565,854...121,576,654

G

deoxyribonuclease 1 like 2

decreases expression

Zearalenone results in decreased expression of DNASE1L2 mRNA

NCBI chr 3:39,757,725...39,761,497
Ensembl chr 3:39,757,296...39,761,080

G

dynamin 1

decreases expression

Zearalenone results in decreased expression of DNM1 mRNA

NCBI chr 1:268,653,045...268,702,233
Ensembl chr 1:268,653,070...268,702,222

G

desmoglein 3

increases expression

Zearalenone results in increased expression of DSG3 mRNA

NCBI chr 6:115,352,005...115,383,750
Ensembl chr 6:115,351,925...115,383,743

G

EBF transcription factor 3

increases expression

Zearalenone results in increased expression of EBF3 mRNA

NCBI chr14:138,819,846...138,935,504
Ensembl chr14:138,819,848...138,935,462

G

E74 like ETS transcription factor 5

affects expression

Zearalenone affects the expression of ELF5 mRNA

NCBI chr 2:26,443,979...26,486,802
Ensembl chr 2:26,443,977...26,485,903

G

epiphycan

decreases expression

Zearalenone results in decreased expression of EPYC mRNA

NCBI chr 5:91,837,672...91,877,779
Ensembl chr 5:91,832,291...91,877,982

G

estrogen receptor 1

increases expression

Zearalenone results in increased expression of ESR1 mRNA

NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363

G

exostosin like glycosyltransferase 1

decreases expression

Zearalenone results in decreased expression of EXTL1 mRNA

NCBI chr 6:83,461,421...83,476,601
Ensembl chr 6:83,462,323...83,476,596

G

family with sequence similarity 184 member B

increases expression

Zearalenone results in increased expression of FAM184B mRNA

NCBI chr 8:12,635,359...12,741,482
Ensembl chr 8:12,634,377...12,741,488

G

fibrinogen C domain containing 1

increases expression

Zearalenone results in increased expression of FIBCD1 mRNA

NCBI chr 1:270,919,793...270,956,753
Ensembl chr 1:270,918,251...270,956,347

G

flavin containing dimethylaniline monoxygenase 1

decreases expression

Zearalenone results in decreased expression of FMO1 mRNA

PMID:25455459 PMID:34933075

NCBI chr 9:63,860,957...63,895,086
Ensembl chr 9:63,868,064...63,895,076

G

fibronectin type III domain containing 4

decreases expression

Zearalenone results in decreased expression of FNDC4 mRNA

NCBI chr 3:111,677,569...111,682,496
Ensembl chr 3:111,678,892...111,682,426

G

FERM and PDZ domain containing 4

decreases expression

Zearalenone results in decreased expression of FRMPD4 mRNA

NCBI chr X:8,625,039...9,451,433
Ensembl chr X:8,542,382...9,438,821

G

follicle stimulating hormone subunit beta

multiple interactions

Zearalenone inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP11A1 mRNA]; Zearalenone inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP19A1 mRNA]; Zearalenone promotes the reaction [FSHB protein results in increased abundance of Progesterone]

NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274

G

follistatin

decreases expression

Zearalenone results in decreased expression of FST mRNA

NCBI chr16:32,806,341...32,811,382
Ensembl chr16:32,805,932...32,811,421

G

polypeptide N-acetylgalactosaminyltransferase 12

affects expression

Zearalenone affects the expression of GALNT12 mRNA

NCBI chr 1:240,595,423...240,639,625
Ensembl chr 1:240,595,394...240,640,563

G

polypeptide N-acetylgalactosaminyltransferase 6

increases expression

Zearalenone results in increased expression of GALNT6 mRNA

G

galanin receptor 1

decreases expression

Zearalenone results in decreased expression of GALR1 mRNA

NCBI chr 1:147,442,977...147,466,731
Ensembl chr 1:147,443,821...147,463,542

G

glutamate-cysteine ligase catalytic subunit

affects expression
increases expression

Zearalenone affects the expression of GCLC protein
Zearalenone results in increased expression of GCLC mRNA

NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530

G

glutamate-cysteine ligase modifier subunit

affects expression
increases expression

Zearalenone affects the expression of GCLM mRNA; Zearalenone affects the expression of GCLM protein
Zearalenone results in increased expression of GCLM mRNA

NCBI chr 4:123,371,198...123,390,130
Ensembl chr 4:123,371,193...123,390,131

G

glucosaminyl (N-acetyl) transferase 3, mucin type

decreases expression

Zearalenone results in decreased expression of GCNT3 mRNA

NCBI chr 1:112,424,212...112,540,984
Ensembl chr 1:112,422,879...112,540,983

G

growth differentiation factor 7

decreases expression

Zearalenone results in decreased expression of GDF7 mRNA

NCBI chr 3:117,586,188...117,592,541
Ensembl chr 3:117,587,430...117,592,466

G

growth differentiation factor 9

decreases expression

Zearalenone results in decreased expression of GDF9 mRNA

NCBI chr 2:135,181,494...135,184,451
Ensembl chr 2:135,181,089...135,187,026

G

glycerophosphodiester phosphodiesterase domain containing 1

decreases expression

Zearalenone results in decreased expression of GDPD1 mRNA

NCBI chr12:35,481,194...35,527,588
Ensembl chr12:35,481,215...35,528,092

G

gap junction protein alpha 1

decreases expression

Zearalenone results in decreased expression of GJA1 mRNA

NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156

G

gap junction protein alpha 4

decreases expression

Zearalenone results in decreased expression of GJA4 mRNA

NCBI chr 6:91,045,430...91,048,161
Ensembl chr 6:91,045,394...91,048,162

G

GLI family zinc finger 2

decreases expression

Zearalenone results in decreased expression of GLI2 mRNA

NCBI chr15:30,312,528...30,580,272
Ensembl chr15:30,313,817...30,579,306

G

glycosyltransferase 6 domain containing 1

decreases expression

Zearalenone results in decreased expression of GLT6D1 mRNA

G

G protein subunit alpha i2

increases expression

Zearalenone results in increased expression of GNAI2 mRNA

NCBI chr13:32,705,326...32,733,804
Ensembl chr13:32,705,321...32,733,794

G

G protein subunit alpha o1

decreases expression

Zearalenone results in decreased expression of GNAO1 mRNA

NCBI chr 6:29,416,574...29,592,874
Ensembl chr 6:29,416,708...29,592,516

G

glutathione peroxidase 1

increases expression

Zearalenone results in increased expression of GPX1 mRNA; Zearalenone results in increased expression of GPX1 protein

PMID:23727178 PMID:31760079

NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433

G

glutathione peroxidase 6

increases expression

Zearalenone results in increased expression of GPX6 mRNA

NCBI chr 7:22,256,013...22,267,992
Ensembl chr 7:22,256,038...22,267,992

G

growth factor receptor bound protein 10

decreases expression

Zearalenone results in decreased expression of GRB10 mRNA

NCBI chr 9:136,580,363...136,742,552
Ensembl chr 9:136,580,362...136,741,756

G

glutamate ionotropic receptor delta type subunit 2

decreases expression

Zearalenone results in decreased expression of GRID2 mRNA

NCBI chr 8:125,821,195...127,130,617
Ensembl chr 8:125,819,951...127,129,763

G

glutathione-disulfide reductase

multiple interactions

Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]]; fumonisin B1 promotes the reaction [Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]; Zearalenone promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]; Zearalenone promotes the reaction [fumonisin B1 promotes the reaction [deoxynivalenol results in decreased activity of GSR protein]]

NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984

G

general transcription factor IIIC subunit 4

increases expression

Zearalenone results in increased expression of GTF3C4 mRNA

NCBI chr 1:272,454,488...272,479,968
Ensembl chr 1:272,454,503...272,479,952

G

gametocyte specific factor 1

increases expression

Zearalenone results in increased expression of GTSF1 mRNA

NCBI chr 5:19,639,326...19,661,773
Ensembl chr 5:19,645,135...19,661,599

G

hephaestin

increases expression

Zearalenone results in increased expression of HEPH mRNA

NCBI chr X:52,314,911...52,397,384
Ensembl chr X:52,314,935...52,397,380

G

heme oxygenase 1

affects expression
decreases expression
multiple interactions

Zearalenone affects the expression of HMOX1 mRNA; Zearalenone affects the expression of HMOX1 protein
Zearalenone results in decreased expression of HMOX1 mRNA; Zearalenone results in decreased expression of HMOX1 protein
[Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of HMOX1 mRNA]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of HMOX1 protein]]; Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of HMOX1 mRNA]; Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of HMOX1 protein]

PMID:31760079 PMID:35489465

G

homeobox A10

decreases expression

Zearalenone results in decreased expression of HOXA10 mRNA

NCBI chr18:45,393,525...45,403,259
Ensembl chr18:45,393,885...45,403,257

G

interferon gamma

multiple interactions
increases expression

[Zearalenone co-treated with deoxynivalenol] results in decreased expression of IFNG mRNA; Zearalenone results in decreased expression of and results in decreased secretion of IFNG protein; Zearalenone results in increased expression of and results in increased secretion of IFNG protein
Zearalenone results in increased expression of IFNG mRNA

PMID:18296887 PMID:23727178 PMID:34933075

NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670

G

insulin like growth factor 1

decreases expression
multiple interactions

Zearalenone results in decreased expression of IGF1 mRNA; Zearalenone results in decreased expression of IGF1 protein
Zearalenone affects the reaction [IGF1 protein results in increased abundance of Estradiol]; Zearalenone inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP11A1 mRNA]; Zearalenone inhibits the reaction [[FSHB protein co-treated with IGF1 protein] results in increased expression of CYP19A1 mRNA]; Zearalenone promotes the reaction [IGF1 protein results in increased abundance of Progesterone]

PMID:17656051 PMID:29758222

NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,033

G

insulin like growth factor binding protein 5

decreases expression

Zearalenone results in decreased expression of IGFBP5 mRNA

NCBI chr15:118,861,816...118,877,787
Ensembl chr15:118,857,625...118,878,120

G

immunoglobulin superfamily member 3

decreases expression

Zearalenone results in decreased expression of IGSF3 mRNA

NCBI chr 4:104,044,784...104,167,173
Ensembl chr 4:103,994,390...104,166,988

G

immunoglobulin superfamily member 5

increases expression

Zearalenone results in increased expression of IGSF5 mRNA

NCBI chr13:203,325,385...203,372,361

G

immunoglobulin superfamily member 9B

decreases expression

Zearalenone results in decreased expression of IGSF9B mRNA

NCBI chr 9:60,467,321...60,521,463
Ensembl chr 9:60,478,029...60,521,465

G

interleukin 10

multiple interactions
decreases expression
increases expression

Zearalenone results in decreased expression of and results in decreased secretion of IL10 protein
Zearalenone results in decreased expression of IL10 mRNA
Zearalenone results in increased expression of IL10 protein

PMID:23727178 PMID:34933075

NCBI chr 9:67,400,727...67,405,941
Ensembl chr 9:67,400,728...67,405,378

G

interleukin 18

multiple interactions
increases expression

[Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA]

PMID:25455459 PMID:30270565

NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219

G

interleukin 1 alpha

multiple interactions
increases expression

[deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone] results in decreased expression of IL1A mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone] results in decreased expression of IL1A mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of IL1A mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1A mRNA
Zearalenone results in increased expression of IL1A mRNA

NCBI chr 3:43,718,320...43,731,668
Ensembl chr 3:43,718,368...43,731,119

G

interleukin 2

multiple interactions
increases expression

[Zearalenone co-treated with deoxynivalenol] results in decreased expression of IL2 mRNA
Zearalenone results in increased expression of IL2 mRNA

PMID:18296887 PMID:34933075

NCBI chr 8:101,640,938...101,645,683
Ensembl chr 8:101,640,944...101,645,609

G

interleukin 22 receptor subunit alpha 1

increases expression

Zearalenone results in increased expression of IL22RA1 mRNA

NCBI chr 6:81,867,849...81,885,017
Ensembl chr 6:81,867,848...81,884,996

G

interleukin 23 receptor

decreases expression

Zearalenone results in decreased expression of IL23R mRNA

NCBI chr 6:145,337,765...145,401,909
Ensembl chr 6:145,335,741...145,401,510

G

interleukin 4

multiple interactions

Zearalenone results in decreased expression of and results in decreased secretion of IL4 protein

NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365

G

interleukin 6

increases expression
multiple interactions

Zearalenone results in increased expression of IL6 mRNA; Zearalenone results in increased expression of IL6 protein
[deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone] results in decreased expression of IL6 mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of IL6 mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL6 mRNA; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of IL6 protein]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of IL6 protein]

PMID:23688591 PMID:32783910 PMID:34933075

NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263

G

inhibin subunit beta A

increases expression

Zearalenone results in increased expression of INHBA mRNA

NCBI chr12:53,115,379...53,117,128
NCBI chr18:52,889,684...52,909,260
Ensembl chr18:52,889,684...52,900,967

G

inositol hexakisphosphate kinase 3

decreases expression

Zearalenone results in decreased expression of IP6K3 mRNA

NCBI chr 7:29,938,779...29,961,520
Ensembl chr 7:29,931,925...29,961,466

G

iroquois homeobox 3

increases expression

Zearalenone results in increased expression of IRX3 mRNA

NCBI chr 6:31,044,919...31,049,067
Ensembl chr 6:31,046,146...31,049,054

G

immunoglobulin superfamily containing leucine rich repeat 2

decreases expression

Zearalenone results in decreased expression of ISLR2 mRNA

NCBI chr 7:59,385,021...59,393,185
Ensembl chr 7:59,386,241...59,388,481

G

integrin subunit beta 5

increases expression

Zearalenone results in increased expression of ITGB5 mRNA

NCBI chr13:135,468,111...135,587,483
Ensembl chr13:135,467,798...135,587,473

G

jade family PHD finger 2

decreases expression

Zearalenone results in decreased expression of JADE2 mRNA

NCBI chr 2:136,686,056...136,832,004
Ensembl chr 2:136,788,372...136,832,001

G

janus kinase and microtubule interacting protein 2

decreases expression

Zearalenone results in decreased expression of JAKMIP2 mRNA

NCBI chr 2:148,864,445...149,045,921
Ensembl chr 2:148,861,751...149,045,927

G

potassium voltage-gated channel subfamily D member 3

decreases expression

Zearalenone results in decreased expression of KCND3 mRNA

NCBI chr 4:108,394,687...108,621,514
Ensembl chr 4:108,246,237...108,621,510

G

potassium two pore domain channel subfamily K member 3

decreases expression

Zearalenone results in decreased expression of KCNK3 mRNA

NCBI chr 3:112,322,446...112,359,212
Ensembl chr 3:112,322,446...112,359,212

G

kelch like ECH associated protein 1

affects expression
decreases expression

Zearalenone affects the expression of KEAP1 protein
Zearalenone results in decreased expression of KEAP1 mRNA

NCBI chr 2:69,280,940...69,290,267
Ensembl chr 2:69,276,336...69,294,382

G

KH RNA binding domain containing, signal transduction associated 3

decreases expression

Zearalenone results in decreased expression of KHDRBS3 mRNA

NCBI chr 4:6,289,577...6,446,494
Ensembl chr 4:6,282,076...6,446,389

G

KIAA1210 ortholog

decreases expression

Zearalenone results in decreased expression of KIAA1210 mRNA

NCBI chr X:97,581,400...97,651,765

G

KIT proto-oncogene, receptor tyrosine kinase

decreases expression

Zearalenone results in decreased expression of KIT mRNA

NCBI chr 8:41,402,334...41,492,306
Ensembl chr 8:41,402,043...41,493,734

G

kelch domain containing 7A

decreases expression

Zearalenone results in decreased expression of KLHDC7A mRNA

NCBI chr 6:77,022,168...77,030,776
Ensembl chr 6:77,023,865...77,026,255

G

keratin 18

increases expression

Zearalenone results in increased expression of KRT18 mRNA

NCBI chr 5:18,217,686...18,221,432
Ensembl chr 5:18,217,691...18,221,429

G

keratin 6A

increases expression

Zearalenone results in increased expression of KRT6A mRNA

NCBI chr 5:17,830,147...17,851,113
Ensembl chr 5:17,780,928...17,868,402

G

keratin 8

increases expression

Zearalenone results in increased expression of KRT8 mRNA

NCBI chr 5:18,172,423...18,180,277
Ensembl chr 5:18,167,553...18,180,404

G

laminin subunit gamma 3

decreases expression

Zearalenone results in decreased expression of LAMC3 mRNA

NCBI chr 1:271,004,423...271,071,223
Ensembl chr 1:271,004,433...271,071,223

G

leucine rich repeat LGI family member 2

increases expression

Zearalenone results in increased expression of LGI2 mRNA

NCBI chr 8:18,986,549...19,017,238
Ensembl chr 8:18,986,046...19,017,431

G

leucine rich repeat containing G protein-coupled receptor 5

increases expression

Zearalenone results in increased expression of LGR5 mRNA

NCBI chr 5:35,463,257...35,595,234
Ensembl chr 5:35,463,279...35,595,930

G

glutathione S-transferase alpha M14

decreases expression

Zearalenone results in decreased expression of GSTA1 mRNA

NCBI chr 7:46,553,813...46,567,596

G

liver carboxylesterase-like

increases expression

Zearalenone results in increased expression of CES1 mRNA

G

interleukin-1 beta-like

multiple interactions
increases expression

[deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of IL1B mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of IL1B mRNA; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of IL1B protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of IL1B protein]; Zearalenone results in decreased expression of and results in decreased secretion of IL1B protein; Zearalenone results in increased expression of and results in increased secretion of IL1B protein
Zearalenone results in increased expression of IL1B mRNA; Zearalenone results in increased expression of IL1B protein

PMID:23688591 PMID:23727178 PMID:30270565 PMID:32783910 PMID:34933075

G

leucine rich repeat and fibronectin type III domain containing 3

decreases expression

Zearalenone results in decreased expression of LRFN3 mRNA

NCBI chr 6:45,343,846...45,352,779
Ensembl chr 6:45,346,637...45,351,990

G

leucine rich repeat and fibronectin type III domain containing 5

decreases expression

Zearalenone results in decreased expression of LRFN5 mRNA

NCBI chr 1:171,906,130...172,177,726
Ensembl chr 1:171,906,198...172,177,720

G

leucine rich repeat containing 4B

decreases expression

Zearalenone results in decreased expression of LRRC4B mRNA

NCBI chr 6:55,346,787...55,409,876
Ensembl chr 6:55,346,908...55,409,991

G

leucine rich repeats and transmembrane domains 2

decreases expression

Zearalenone results in decreased expression of LRTM2 mRNA

NCBI chr 5:68,821,815...68,836,518
Ensembl chr 5:68,822,539...68,836,514

G

MAP3K7 C-terminal like

decreases expression

Zearalenone results in decreased expression of MAP3K7CL mRNA

NCBI chr13:192,488,937...192,534,826
Ensembl chr13:192,489,751...192,534,821

G

matrix Gla protein

decreases expression

Zearalenone results in decreased expression of MGP mRNA

NCBI chr 5:57,665,272...57,669,360
Ensembl chr 5:57,665,248...57,669,764

G

microRNA mir-331

increases expression

Zearalenone results in increased expression of MIR331 mRNA

NCBI chr 5:88,028,339...88,028,418
Ensembl chr 5:88,028,339...88,028,418

G

microRNA mir-744

increases expression

Zearalenone results in increased expression of MIR744 mRNA

NCBI chr12:56,464,848...56,464,927
Ensembl chr12:56,464,848...56,464,927

G

matrix metallopeptidase 8

increases expression

Zearalenone results in increased expression of MMP8 mRNA

NCBI chr 9:33,384,034...33,397,637
Ensembl chr 9:33,384,033...33,396,947

G

mitochondrially encoded ATP synthase membrane subunit 8

increases expression

Zearalenone results in increased expression of ATP8 mRNA

NCBI chr MT:8,959...9,162
Ensembl chr MT:8,959...9,162

G

mucin 5B, oligomeric mucus/gel-forming

increases expression

Zearalenone results in increased expression of MUC5B mRNA

NCBI chr 2:807,685...842,096

G

matrix remodeling associated 7

decreases expression

Zearalenone results in decreased expression of MXRA7 mRNA

NCBI chr12:4,822,306...4,866,818

G

myosin heavy chain 11

decreases expression

Zearalenone results in decreased expression of MYH11 mRNA

NCBI chr 3:7,002,667...7,143,093
Ensembl chr 3:7,002,735...7,143,095

G

myosin heavy chain 13

decreases expression

Zearalenone results in decreased expression of MYH13 mRNA

NCBI chr12:55,051,990...55,103,415
Ensembl chr12:55,046,888...55,103,400

G

myosin heavy chain 7

increases expression

Zearalenone results in increased expression of MYH7 mRNA

NCBI chr 7:75,650,841...75,672,908
Ensembl chr 7:75,648,442...75,673,225

G

NDRG family member 4

decreases expression

Zearalenone results in decreased expression of NDRG4 mRNA

NCBI chr 6:20,222,876...20,265,581
Ensembl chr 6:20,223,667...20,265,576

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
decreases expression

Zearalenone results in increased expression of NFE2L2 mRNA; Zearalenone results in increased expression of NFE2L2 protein
[Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of HMOX1 mRNA]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of HMOX1 protein]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NFE2L2 mRNA]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NFE2L2 protein]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NQO1 mRNA]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NQO1 protein]]; Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NFE2L2 mRNA]; Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NFE2L2 protein]
Zearalenone results in decreased expression of NFE2L2 mRNA; Zearalenone results in decreased expression of NFE2L2 protein

PMID:31760079 PMID:35489465

NCBI chr15:82,967,485...83,146,185
Ensembl chr15:82,973,656...83,146,183

G

NHS like 2

decreases expression

Zearalenone results in decreased expression of NHSL2 mRNA

NCBI chr X:57,741,172...58,028,266
Ensembl chr X:57,742,114...58,030,951

G

NLR family CARD domain containing 3

decreases expression

Zearalenone results in decreased expression of NLRC3 mRNA

NCBI chr 3:38,673,590...38,719,188
Ensembl chr 3:38,687,967...38,710,938

G

NLR family pyrin domain containing 3

multiple interactions
increases expression

[Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]
Zearalenone results in increased expression of NLRP3 mRNA; Zearalenone results in increased expression of NLRP3 protein

NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228

G

nitric oxide synthase 2

increases expression
decreases expression

Zearalenone results in increased expression of NOS2 mRNA
Zearalenone results in decreased expression of NOS2 mRNA

NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146

G

notch receptor 1

decreases expression

Zearalenone results in decreased expression of NOTCH1 mRNA

G

NADPH oxidase 4

decreases expression

Zearalenone results in decreased expression of NOX4 mRNA

NCBI chr 9:22,622,105...22,776,691
Ensembl chr 9:22,624,212...22,776,534

G

NAD(P)H quinone dehydrogenase 1

affects expression
multiple interactions
decreases expression

Zearalenone affects the expression of NQO1 mRNA; Zearalenone affects the expression of NQO1 protein
[Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NQO1 mRNA]]; [Heterocyclic Compounds results in decreased activity of NFE2L2 protein] inhibits the reaction [Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NQO1 protein]]; Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NQO1 mRNA]; Proanthocyanidins inhibits the reaction [Zearalenone results in decreased expression of NQO1 protein]
Zearalenone results in decreased expression of NQO1 mRNA; Zearalenone results in decreased expression of NQO1 protein

PMID:31760079 PMID:35489465

NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,770...17,302,590

G

nuclear receptor subfamily 2 group F member 1

decreases expression

Zearalenone results in decreased expression of NR2F1 mRNA

NCBI chr 2:100,447,661...100,457,510
Ensembl chr 2:100,447,705...100,457,506

G

nuclear receptor binding protein 2

decreases expression

Zearalenone results in decreased expression of NRBP2 mRNA

NCBI chr 4:800,722...808,031
Ensembl chr 4:800,063...807,174

G

neurotrophic receptor tyrosine kinase 3

decreases expression

Zearalenone results in decreased expression of NTRK3 mRNA

NCBI chr 1:191,535,262...191,941,675
Ensembl chr 1:191,535,301...191,925,327

G

odd-skipped related transciption factor 2

decreases expression

Zearalenone results in decreased expression of OSR2 mRNA

NCBI chr 4:37,890,200...37,897,935
Ensembl chr 4:37,890,203...37,897,929

G

p21 (RAC1) activated kinase 4

decreases expression

Zearalenone results in decreased expression of PAK4 mRNA; Zearalenone results in decreased expression of PAK4 protein

NCBI chr 6:47,869,604...47,914,185
Ensembl chr 6:47,869,577...47,914,182

G

p21 (RAC1) activated kinase 5

increases expression

Zearalenone results in increased expression of PAK5 mRNA

NCBI chr17:18,461,060...18,785,869
Ensembl chr17:18,461,062...18,785,313

G

p21 (RAC1) activated kinase 6

increases expression

Zearalenone results in increased expression of PAK6 mRNA

NCBI chr 1:131,039,313...131,077,420
Ensembl chr 1:131,039,318...131,076,631

G

pappalysin 1

decreases expression

Zearalenone results in decreased expression of PAPPA mRNA

NCBI chr 1:256,544,496...256,784,813
Ensembl chr 1:256,544,928...256,780,760

G

protocadherin 11 X-linked

decreases expression

Zearalenone results in decreased expression of PCDH11X mRNA

NCBI chr X:74,462,811...75,191,930

G

phosphodiesterase 10A

decreases expression

Zearalenone results in decreased expression of PDE10A mRNA

NCBI chr 1:3,120,418...3,394,236
Ensembl chr 1:2,829,411...3,392,651

G

platelet derived growth factor receptor alpha

decreases expression

Zearalenone results in decreased expression of PDGFRA mRNA

NCBI chr 8:40,966,568...41,021,440
Ensembl chr 8:40,967,493...41,021,441

G

peptidoglycan recognition protein 3

increases expression

Zearalenone results in increased expression of PGLYRP3 mRNA

NCBI chr 4:96,261,753...96,277,521
Ensembl chr 4:96,261,775...96,277,521

G

plexin domain containing 1

decreases expression

Zearalenone results in decreased expression of PLXDC1 mRNA

NCBI chr12:23,073,292...23,142,529
Ensembl chr12:23,073,302...23,142,547

G

protein kinase AMP-activated non-catalytic subunit gamma 3

decreases expression

Zearalenone results in decreased expression of PRKAG3 mRNA

NCBI chr15:120,859,486...120,866,308
Ensembl chr15:120,855,201...120,866,332

G

protamine 2

increases expression

Zearalenone results in increased expression of PRM2 mRNA

NCBI chr 3:31,864,350...31,864,959
Ensembl chr 3:31,864,350...31,864,961

G

proline rich transmembrane protein 1

decreases expression

Zearalenone results in decreased expression of PRRT1 mRNA

NCBI chr 7:24,183,557...24,186,892
Ensembl chr 7:24,180,637...24,186,908

G

proteasome 20S subunit beta 8

increases expression

Zearalenone results in increased expression of PSMB8 mRNA

NCBI chr 7:25,058,456...25,061,666
Ensembl chr 7:25,058,465...25,062,245

G

prostaglandin-endoperoxide synthase 2

increases expression
decreases expression

Zearalenone results in increased expression of PTGS2 mRNA
Zearalenone results in decreased expression of PTGS2 mRNA

NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884

G

pentraxin 3

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of PTX3 mRNA]

NCBI chr13:97,273,594...97,279,570
Ensembl chr13:97,273,594...97,279,569

G

PYD and CARD domain containing

multiple interactions
increases expression

[Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein
Zearalenone results in increased expression of PYCARD mRNA; Zearalenone results in increased expression of PYCARD protein

NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,099...17,307,786

G

Ras protein specific guanine nucleotide releasing factor 2

decreases expression

Zearalenone results in decreased expression of RASGRF2 mRNA

NCBI chr 2:89,525,948...89,794,103
Ensembl chr 2:89,528,111...89,790,719

G

RAS guanyl releasing protein 1

increases expression

Zearalenone results in increased expression of RASGRP1 mRNA

NCBI chr 1:132,702,495...132,786,536
Ensembl chr 1:132,702,541...132,786,532

G

RBBP8 N-terminal like

increases expression

Zearalenone results in increased expression of RBBP8NL mRNA

NCBI chr17:61,778,579...61,794,258
Ensembl chr17:61,782,605...61,787,321

G

retinol dehydrogenase 12

increases expression

Zearalenone results in increased expression of RDH12 mRNA

NCBI chr 7:91,481,238...91,493,838
Ensembl chr 7:91,481,272...91,493,809

G

regucalcin

increases expression

Zearalenone results in increased expression of RGN mRNA

NCBI chr X:41,725,660...41,749,736
Ensembl chr X:41,726,526...41,749,381

G

regulator of G protein signaling 16

increases expression

Zearalenone results in increased expression of RGS16 mRNA

NCBI chr 9:123,913,179...123,919,119
Ensembl chr 9:123,913,173...123,918,871

G

regulator of G protein signaling 6

decreases expression

Zearalenone results in decreased expression of RGS6 mRNA

NCBI chr 7:95,365,212...95,930,040
Ensembl chr 7:95,365,939...95,930,034

G

Rh family C glycoprotein

increases expression

Zearalenone results in increased expression of RHCG mRNA

NCBI chr 7:55,046,244...55,071,504
Ensembl chr 7:55,046,245...55,071,475

G

RIPOR family member 3

decreases expression

Zearalenone results in decreased expression of RIPOR3 mRNA

NCBI chr17:52,088,049...52,163,964
Ensembl chr17:52,088,053...52,162,554

G

ring finger protein 186

increases expression

Zearalenone results in increased expression of RNF186 mRNA

NCBI chr 6:78,195,692...78,199,058
Ensembl chr 6:78,192,337...78,198,597

G

reprimo like

decreases expression

Zearalenone results in decreased expression of RPRML mRNA

NCBI chr12:17,816,889...17,818,910
Ensembl chr12:17,816,890...17,818,047

G

RUNX1 partner transcriptional co-repressor 1

decreases expression

Zearalenone results in decreased expression of RUNX1T1 mRNA

NCBI chr 4:44,600,292...44,745,954
Ensembl chr 4:44,599,760...44,743,418

G

relaxin family peptide receptor 2

decreases expression

Zearalenone results in decreased expression of RXFP2 mRNA

NCBI chr11:8,266,898...8,321,021
Ensembl chr11:8,282,517...8,321,020

G

S100 calcium binding protein A12

increases expression

Zearalenone results in increased expression of S100A12 mRNA

NCBI chr 4:96,225,691...96,227,030
Ensembl chr 4:96,225,691...96,227,127

G

S100 calcium binding protein A8

increases expression

Zearalenone results in increased expression of S100A8 mRNA

NCBI chr 4:96,209,670...96,210,603
Ensembl chr 4:96,209,659...96,210,602

G

S100 calcium binding protein A9

increases expression

Zearalenone results in increased expression of S100A9 mRNA

NCBI chr 4:96,236,114...96,238,989

G

somatomedin B and thrombospondin type 1 domain containing

decreases expression

Zearalenone results in decreased expression of SBSPON mRNA

NCBI chr 4:62,756,262...62,791,621
Ensembl chr 4:62,756,342...62,791,609

G

scavenger receptor class A member 5

decreases expression

Zearalenone results in decreased expression of SCARA5 mRNA

NCBI chr14:11,615,629...11,747,336

G

sodium voltage-gated channel alpha subunit 4

decreases expression

Zearalenone results in decreased expression of SCN4A mRNA

NCBI chr12:15,001,356...15,048,092
Ensembl chr12:15,002,175...15,047,582

G

sodium channel epithelial 1 subunit gamma

increases expression

Zearalenone results in increased expression of SCNN1G mRNA

NCBI chr 3:22,977,940...23,013,384
Ensembl chr 3:22,977,947...23,013,384

G

selenium binding protein 1

decreases expression

Zearalenone results in decreased expression of SELENBP1 mRNA

NCBI chr 4:97,860,925...97,894,007
Ensembl chr 4:97,837,981...97,894,301

G

serpin family B member 11

increases expression

Zearalenone results in increased expression of SERPINB11 mRNA

NCBI chr 1:158,015,714...158,030,833
Ensembl chr 1:158,015,718...158,030,763

G

serpin family B member 2

increases expression

Zearalenone results in increased expression of SERPINB2 mRNA

NCBI chr 1:157,871,919...157,886,525
Ensembl chr 1:157,872,212...157,886,602

G

serum/glucocorticoid regulated kinase 2

increases expression

Zearalenone results in increased expression of SGK2 mRNA

NCBI chr17:46,188,160...46,208,807
Ensembl chr17:46,188,265...46,208,804

G

hyaluronan synthase 2

decreases expression

Zearalenone results in decreased expression of SHAS2 mRNA

NCBI chr 4:17,583,154...17,613,524
Ensembl chr 4:17,596,492...17,615,480

G

solute carrier family 16 member 12

increases expression

Zearalenone results in increased expression of SLC16A12 mRNA

NCBI chr14:101,273,977...101,368,350
Ensembl chr14:101,273,996...101,368,132

G

solute carrier family 25 member 48

increases expression

Zearalenone results in increased expression of SLC25A48 mRNA

NCBI chr 2:137,979,811...138,035,582
Ensembl chr 2:137,986,828...138,035,578

G

solute carrier family 2 member 7

increases expression

Zearalenone results in increased expression of SLC2A7 mRNA

NCBI chr 6:69,483,736...69,503,758
Ensembl chr 6:69,484,227...69,503,732

G

solute carrier family 9 member A5

decreases expression

Zearalenone results in decreased expression of SLC9A5 mRNA

NCBI chr 6:27,883,163...27,904,076
Ensembl chr 6:27,884,592...27,904,075

G

slit guidance ligand 3

decreases expression

Zearalenone results in decreased expression of SLIT3 mRNA

NCBI chr16:54,551,536...55,221,427
Ensembl chr16:54,553,426...55,220,296

G

sushi, nidogen and EGF like domains 1

decreases expression

Zearalenone results in decreased expression of SNED1 mRNA

NCBI chr15:139,821,021...139,881,099
Ensembl chr15:139,821,062...139,881,095

G

superoxide dismutase 1

decreases expression

Zearalenone results in decreased expression of SOD1 mRNA

NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729

G

sortilin related VPS10 domain containing receptor 2

decreases expression

Zearalenone results in decreased expression of SORCS2 mRNA

NCBI chr 8:3,207,087...3,715,002
Ensembl chr 8:3,207,098...3,760,393

G

SPARC like 1

decreases expression

Zearalenone results in decreased expression of SPARCL1 mRNA

NCBI chr 8:131,386,804...131,431,427
Ensembl chr 8:131,386,973...131,431,200

G

SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1

affects expression

Zearalenone affects the expression of SPOCK1 mRNA

NCBI chr 2:139,018,177...139,523,601
Ensembl chr 2:139,018,179...139,522,593

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2

decreases expression

Zearalenone results in decreased expression of ST8SIA2 mRNA

NCBI chr 7:86,450,302...86,514,232
Ensembl chr 7:86,446,149...86,514,393

G

signal transducer and activator of transcription 5B

increases expression

Zearalenone results in increased expression of STAT5B mRNA

NCBI chr12:20,498,103...20,574,365
Ensembl chr12:20,508,404...20,574,266

G

signal transducer and activator of transcription 6

increases expression

Zearalenone results in increased expression of STAT6 mRNA

NCBI chr 5:22,406,356...22,422,412
Ensembl chr 5:22,406,368...22,421,989

G

transforming acidic coiled-coil containing protein 1

decreases expression

Zearalenone results in decreased expression of TACC1 mRNA

NCBI chr15:47,749,079...47,861,200

G

tyrosine aminotransferase

increases expression

Zearalenone results in increased expression of TAT mRNA

NCBI chr 6:14,571,311...14,583,203
Ensembl chr 6:14,570,589...14,583,177

G

T-box transcription factor 20

increases expression

Zearalenone results in increased expression of TBX20 mRNA

NCBI chr18:38,635,603...38,681,690
Ensembl chr18:38,635,617...38,678,133

G

trefoil factor 2

increases expression

Zearalenone results in increased expression of TFF2 mRNA

NCBI chr13:205,669,014...205,672,319
Ensembl chr13:205,669,014...205,672,324

G

transglutaminase 2

decreases expression

Zearalenone results in decreased expression of TGM2 mRNA

NCBI chr17:41,186,765...41,221,686
Ensembl chr17:41,186,770...41,221,637

G

thrombospondin 1

decreases expression

Zearalenone results in decreased expression of THBS1 mRNA

NCBI chr 1:131,728,781...131,746,098
Ensembl chr 1:131,728,784...131,746,115

G

toll like receptor 2

increases expression

Zearalenone results in increased expression of TLR2 mRNA

NCBI chr 8:75,416,257...75,428,370
Ensembl chr 8:75,411,993...75,428,330

G

toll like receptor 3

decreases expression

Zearalenone results in decreased expression of TLR3 mRNA

NCBI chr15:46,966,262...46,977,774
Ensembl chr15:46,969,006...46,979,291

G

transmembrane protein 171

increases expression

Zearalenone results in increased expression of TMEM171 mRNA

NCBI chr 2:82,287,211...82,297,855
Ensembl chr 2:82,287,158...82,297,856

G

transmembrane protein 200C

decreases expression

Zearalenone results in decreased expression of TMEM200C mRNA

NCBI chr 6:101,211,852...101,217,574
Ensembl chr 6:101,214,902...101,216,782

G

tumor necrosis factor

increases expression
decreases secretion
multiple interactions

Zearalenone results in increased expression of TNF mRNA; Zearalenone results in increased expression of TNF protein
Zearalenone results in decreased secretion of TNF protein
[deoxynivalenol co-treated with nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with nivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; [nivalenol co-treated with Zearalenone] results in increased expression of TNF mRNA; [Zearalenone co-treated with deoxynivalenol] results in decreased expression of TNF mRNA; [Zearalenone co-treated with fumonisin B1] results in increased expression of TNF mRNA; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of TNF protein]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of TNF protein]; Zearalenone results in decreased expression of and results in decreased secretion of TNF protein; Zearalenone results in increased expression of and results in increased secretion of TNF protein

PMID:18296887 PMID:21763767 PMID:23688591 PMID:23727178 PMID:32783910 More...

NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416

G

TNF alpha induced protein 6

decreases expression
multiple interactions

Zearalenone results in decreased expression of TNFAIP6 mRNA
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of TNFAIP6 mRNA]

NCBI chr15:862,013...881,352
Ensembl chr15:862,015...881,461

G

troponin C1, slow skeletal and cardiac type

increases expression

Zearalenone results in increased expression of TNNC1 mRNA

NCBI chr13:34,591,571...34,594,320
Ensembl chr13:34,591,386...34,594,337

G

troponin I1, slow skeletal type

increases expression

Zearalenone results in increased expression of TNNI1 mRNA

NCBI chr10:23,788,279...23,800,554
Ensembl chr10:23,788,279...23,804,119

G

tensin 1

decreases expression

Zearalenone results in decreased expression of TNS1 mRNA

NCBI chr15:119,948,133...120,143,797
Ensembl chr15:119,951,091...120,164,713

G

tensin 2

decreases expression

Zearalenone results in decreased expression of TNS2 mRNA

NCBI chr 5:18,305,488...18,320,784
Ensembl chr 5:18,300,167...18,320,781

G

tumor protein p53

increases expression
multiple interactions

Zearalenone results in increased expression of TP53 mRNA
Acetylcysteine inhibits the reaction [fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]]; Acetylcysteine inhibits the reaction [Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]]; Acetylcysteine promotes the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]; fumonisin B1 inhibits the reaction [deoxynivalenol inhibits the reaction [Zearalenone results in increased expression of TP53 mRNA]]; fumonisin B1 promotes the reaction [Zearalenone results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [[deoxynivalenol co-treated with fumonisin B1] results in increased expression of TP53 mRNA]; Zearalenone promotes the reaction [fumonisin B1 results in increased expression of TP53 mRNA]

NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818

G

triggering receptor expressed on myeloid cells 2

decreases expression

Zearalenone results in decreased expression of TREM2 mRNA

NCBI chr 7:36,465,921...36,471,509
Ensembl chr 7:36,465,324...36,471,516

G

tripartite motif containing 29

increases expression

Zearalenone results in increased expression of TRIM29 mRNA

NCBI chr 9:47,256,314...47,284,104
Ensembl chr 9:47,256,317...47,284,006

G

uromodulin like 1

decreases expression

Zearalenone results in decreased expression of UMODL1 mRNA

NCBI chr13:205,425,338...205,494,492
Ensembl chr13:205,425,454...205,491,629

G

uroplakin 1A

increases expression

Zearalenone results in increased expression of UPK1A mRNA

NCBI chr 6:45,105,118...45,113,631
Ensembl chr 6:45,104,021...45,114,122

G

uroplakin 1B

increases expression

Zearalenone results in increased expression of UPK1B mRNA

NCBI chr13:141,013,953...141,026,368
Ensembl chr13:141,013,103...141,038,902

G

V-set and transmembrane domain containing 2 like

decreases expression

Zearalenone results in decreased expression of VSTM2L mRNA

NCBI chr17:40,978,558...41,019,847
Ensembl chr17:40,978,794...41,019,845

G

V-set domain containing T cell activation inhibitor 1

increases expression

Zearalenone results in increased expression of VTCN1 mRNA

NCBI chr 4:103,390,547...103,584,847
Ensembl chr 4:103,412,571...103,584,683

G

WD repeat domain 97

decreases expression

Zearalenone results in decreased expression of WDR97 mRNA

NCBI chr 4:588,629...597,333

G

zinc finger and BTB domain containing 16

decreases expression

Zearalenone results in decreased expression of ZBTB16 mRNA

NCBI chr 9:41,639,536...41,839,254
Ensembl chr 9:41,639,701...41,836,742

G

zinc finger E-box binding homeobox 1

decreases expression

Zearalenone results in decreased expression of ZEB1 mRNA

NCBI chr10:42,013,114...42,216,139
Ensembl chr10:42,013,084...42,214,205

G

zinc finger protein 275

decreases expression

Zearalenone results in decreased expression of ZNF275 mRNA

NCBI chr X:124,156,708...124,173,566

G

zinc finger protein 750

increases expression

Zearalenone results in increased expression of ZNF750 mRNA

NCBI chr12:398,498...407,812

G

zona pellucida glycoprotein 3

decreases expression
multiple interactions

Zearalenone results in decreased expression of ZP3 mRNA
Acetylcysteine inhibits the reaction [Zearalenone results in decreased expression of ZP3 mRNA]

NCBI chr 3:9,934,760...9,944,924
Ensembl chr 3:9,934,761...9,944,941

G

zinc finger and SCAN domain containing 23

decreases expression

Zearalenone results in decreased expression of ZSCAN23 mRNA

NCBI chr 7:22,216,543...22,229,304
Ensembl chr 7:22,215,053...22,229,218

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	5081
chemical entity	5081
molecular entity	5080
polyatomic entity	5060
heteroatomic molecular entity	5029
hydroxides	4863
organic hydroxy compound	4793
phenols	644
benzenediols	494
resorcinols	488
(+)-microdiplodiasone	0
(-)-(S)-chlorizidine A	0
(2R,4R,12S)-16,18-dihydroxy-12-methyl-3,13-dioxatricyclo[13.4.0.02,4]nonadeca-1(15),16,18-triene-8,14-dione	0
(2R,4R,12S)-16-hydroxy-18-methoxy-12-methyl-3,13-dioxatricyclo[13.4.0.02,4]nonadeca-1(15),16,18-triene-8,14-dione	0
(3,5-dihydroxyphenyl)acetic acid	0
(3R,4R)-7,2',4'-trihydroxyisoflavanol	0
(5S)-2-(3,5-dihydroxyphenyl)-5-hydroxy-3-methylcyclopent-2-en-1-one	0
(5S,6S,11S)-5,6,15-trihydroxy-17-methoxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,8,15,17-pentaene-7,13-dione	0
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside	0
(E)-Antibiotic BE 23372M	0
(S)-1-(3,5-dihydroxy-4-methylphenyl)-4-hydroxypentan-2-one	0
(S)-3,5-dihydroxyphenylglycine	0
(S,E)-1-(3,5-dihydroxyphenyl)-10-hydroxyundec-1-en-6-one	0
(S,E)-2,4-dihydroxy-6-(10-hydroxy-6-oxoundec-1-en-1-yl)benzoate	0
(S,E)-Zearalenone	0
1''-hydroxycannabidiol	0
1-(3,5-Dihydroxyphenyl)-2-pentadecanone	0
1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one	0
1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)pentan-1-one	0
1-(3,5-dihydroxyphenyl)-4-hydroxypentan-2-one	0
15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,15,17-tetraene-7,13-dione	0
15-O-desmethyl-(5Z)-7-oxozeaenol	0
2''-hydroxycannabidiol	0
2',4'-dihydroxy-3'-(2-hydroxy benzyl)-6'-methoxy chalcone	0
2',4'-dihydroxy-3'-methyl-6'-methoxychalcone	0
2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone	0
2',4'-dihydroxyacetophenone	0
2',6'-dihydroxy-4'-methoxyacetophenone	0
2,4-Bis(3-methylbut-2-enyl)-5-pentylbenzene-1,3-diol	0
2-(2,4-dihydroxy-5-prenylphenyl)-5,6-methylenedioxybenzofuran	0
2-(2,4-dihydroxyphenyl)-5-(E)-propenylbenzofuran	0
2-Hydroxy-4-methoxy-6-[(4R,5S,7Z,10S)-4,5,10-trihydroxy-6-oxo-7-undecenyl]benzoic acid mu-lactone	0
2-Methyl-5-(8-pentadecenyl)-1,3-benzenediol	0
2-[2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl]-2-hydroxyacetic acid	0
2-hexyl-5-(5-hydroxypentyl)resorcinol	0
2-hexyl-5-(7-carboxyheptyl)resorcinol	0
2-hexyl-5-(7-hydroxyheptyl)resorcinol	0
2-hexyl-5-(7-oxoheptyl)resorcinol	0
2-hexyl-5-heptylresorcinol	0
2-hexyl-5-methylresorcinol	0
2-hexyl-5-pentylresorcinol	0
3''-hydroxycannabidiol	0
3,3',5-trihydroxybibenzyl	0
3,4,5-trihydroxy-6-[(14-hydroxy-3-methyl-1,7-dioxo-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-16-yl)oxy]oxane-2-carboxylic acid	0
3,5-dihydroxybenzoic acid	0
3,5-dihydroxyphenylglyoxylic acid	0
3,5-dimethylorsellinic acid	0
3-(3,5-dihydroxyphenyl)-1-propanoic acid sulphate	0
3-methylorsellinic acid	0
4''-hydroxycannabidiol	0
4-(2,4-dihydroxyphenyl)butan-2-one	0
4-(4-nitrophenylazo)resorcinol	0
4-Acetylzearalenone	0
4-Ethylresorcinol	0
4-O-demethylhypothemycin	0
4-O-methylxanthohumol	0
4-Vinylresorcinol	0
4-chloro-6-\{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl\}benzene-1,3-diol	0
4-hexylbenzene-1,3-diol	0
4-hydroxy-5-propionyl-1,3-di-O-methylpyrogallol	0
4-methyl-5-pentylbenzene-1,3-diol	0
4-n-Butylresorcinol	0
5''-hydroxycannabidiol	0
5'-hydroxyasperentin	0
5-((3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaen-1-yl)resorcinol	0
5-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaen-1-yl)resorcinol	0
5-((5Z,8Z,11Z)-heptadeca-5,8,11-trien-1-yl)resorcinol	0
5-((5Z,8Z,11Z,14Z)-heptadeca-5,8,11,14-tetraen-1-yl)resorcinol	0
5-((7Z,10Z,13Z,16Z)-nonadeca-7,10,13,16-tetraen-1-yl)resorcinol	0
5-((8Z,11Z)-heptadeca-8,11-dien-1-yl)resorcinol	0
5-((8Z,11Z)-nonadeca-8,11-dien-1-yl)resorcinol	0
5-((8Z,11Z,14Z)-heptadeca-8,11,14-trien-1-yl)resorcinol	0
5-((Z)-henicos-14-en-1-yl)resorcinol	0
5-((Z)-nonadec-8-en-1-yl)resorcinol	0
5-(1-amino-2-hydroperoxyethyl)benzene-1,3-diol	0
5-(10,13-Nonadecadienyl)-1,3-benzenediol	0
5-(12,15-Heneicosadienyl)-1,3-benzenediol	0
5-(12-Heptadecenyl)-1,3-benzenediol	0
5-(14-Nonadecenyl)-1,3-benzenediol	0
5-(3',4',5'-Trihydroxyphenyl)-gamma-valerolactone-4'-O-sulphate	0
5-(3',5')-Dihydroxyphenyl-gamma-valerolactone	0
5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide	0
5-(8,11,14-pentadecatrienyl)resorcinol	0
5-(hydroxymethyl)benzene-1,3-diol	0
5-Heneicosyl-1,3-benzenediol	0
5-Nonadecyl-1,3-benzenediol	0
5-Pentacosyl-1,3-benzenediol	0
5-Pentadec-8-enylbenzene-1,3-diol	0
5-[(10E)-Nonadec-10-en-1-yl]benzene-1,3-diol	0
5-[(10Z)-14-(3,5-dihydroxyphenyl)tetradec-10-en-1-yl]benzene-1,3-diol	0
5-[(3E,5E)-3,5-nonadienyl]-1,3-benzenediol	0
5-[(3Z,5E)-3,5-nonadienyl]-1,3-benzenediol	0
5-[(8Z,11Z)-pentadeca-8,11-dien-1-yl]benzene-1,3-diol	0
5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol +	0
5-[12-(3,5-Dihydroxyphenyl)dodecyl]benzene-1,3-diol	0
5-alkatrienylresorcinol +	0
5-alkenylresorcinol +	0
5-alkylresorcinol +	0
5-heptadeca-8′Z,11′Z,16-trienylresorcinol	0
5-heptadeca-9′E,11′Z,16-trienylresorcinol	0
5-methylorsellinic acid	0
5-nonacosylresorcinol	0
5′beta-hydroxyzearalenone	0
6'-O-desmethylterphenyllin	0
6-(2,4-dihydroxyphenyl)-2-(2,6-dihydroxyphenyl)-6-hydroxy-4-methylcyclohex-3-ene-1-carboxylic acid	0
6-[2-(2,4-dihydroxy-6-methylphenyl)-2-oxoethyl]-4-hydroxy-pyran-2-one	0
6-demethylsorbicillin	0
6alpha-hydroxycannabidiol	0
6beta-hydroxycannabidiol	0
7'beta-hydroxyzearalenone	0
7-hydroxycannabidiol	0
8'-hydroxyzearalanone	0
9′alpha-hydroxyzearalenone	0
Adipostatin B	0
Aigialomycin A	0
Albaconol	0
Ascotrichrone A	0
Aspulvinone O	0
CCT-018159	0
Cardol diene	0
Chaetosemin J	0
Cochliomycin D	0
Cochliomycin E	0
Cochliomycin F	0
Cytosporone F	0
Cytosporone T	0
Cytosporone U	0
Demethylsorbicillin	0
Grevillol	0
Hamigeromycin A	0
Hamigeromycin B	0
Hamigeromycin C	0
Hamigeromycin D	0
Hamigeromycin E	0
Hansfordiol B	0
Hansfordiol F	0
ICPD-26	0
ICPD-47	0
Ilyoresorcy G	0
Ilyoresorcy I	0
Integramycin	0
Javanicol C	0
L-783277	0
LL-Z1640-1	0
Microcarbonin A	0
Monavalerolactone	0
Neocosmosin B	0
Neocosmosin C	0
Nostolactone 4	0
Paecilomycin N	0
Paecilomycin O	0
Penicipyran B	0
Peniquinone B	0
Precochlioquinol D	0
Pyrogallol-2-O-sulphate	0
Raistrickione E	0
Resorcinin	0
SCHEMBL7458752	0
Saccharothriolide B	0
Saccharothriolide C	0
Saccharothriolide C2	0
Saccharothriolide E	0
Sch 725681	0
Stemphol	0
TAN-931	0
Terbutaline-1-sulfate	0
Trichosorbicillin I	0
Venemycin	0
Zearalanone	0
Zearalenone 4-sulfate	0
Zobelliphol	0
abyssinone A	0
abyssinone C	0
abyssinone D	0
abyssinone VI	0
alpha-aminoorcein +	0
alpha-hydroxyorcein +	0
anolignan A	0
ardisiphenol A	0
ardisiphenol B	0
ardisiphenol C	0
arugosin A (hydroxy-aldehyde form)	0
ascochlorin	0
ascofuranol	0
ascofuranone	0
asperentin +	0
beta-aminoorceimine +	0
beta-aminoorcein +	0
beta-hydroxyorcein +	0
brartemicin	0
candidachalcone	0
cannabidiol +	0
cannabidiolic acid	0
cannabigerol	0
cannabigerolic acid	0
cannabinerolic acid	0
cephalanone F	0
clavatol +	0
comazaphilone D	0
cytonic acid A	0
cytonic acid B	0
dihydropinosylvin	0
diuvaretin	0
drummondin E	0
eriosemaone C	0
eucalyptal A	0
eucalyptal B	0
eucalyptal C	0
fenoterol +	0
flamenol	0
flavan-3,3',4,4',5,5',7-heptol +	0
furanocandin	0
gaboroquinone A	0
gamma-aminoorceimine +	0
gamma-aminoorcein +	0
gamma-hydroxyorcein +	0
gancaonin I	0
globosumone A	0
globosumone B	0
globosumone C	0
glycycoumarin	0
hydroxyclavatol +	0
hydroxyclavatol ethyl ether	0
hydroxyclavatol methyl ether	0
ilicicolin B	0
integracin A	0
integracin B	0
integracin C	0
isoliquiritin	0
knipholone +	0
kuraridinol	0
kuwanone G	1
kuwanone H	0
leptorumol	0
licoarylcoumarin	0
licocoumarone	0
licodione +	0
littorachalcone	0
luminespib	0
methylophiopogonone A	0
methylophiopogonone B	0
monodictyphenone	0
multifidol glucoside	0
naringin chalcone	0
noreugenin	0
o-orsellinic acid +	0
olivetol +	0
olivetolic acid +	0
onalespib	0
pacein	0
penilactone A	0
penilactone B(1-)	0
penilactone D(2-)	0
peniphenone D(1-)	0
phlorizin chalcone	0
piceatannol +	0
pisonin B	0
pisonin C	0
pisonin F	0
platensimycin A1 methyl ester	0
platensimycin A2 methyl ester	0
platensimycin A3 methyl ester	0
platensimycin A4 methyl ester	0
platensimycin B1	0
platensimycin B3	0
pyoluteorin	0
resorcinol +	0
resveratrol +	226
riodoxol	0
rohitukine	0
schweinfurthin E	0
schweinfurthin F	0
schweinfurthin G	0
soppiline B	0
soppiline C	0
sorocenol H	0
sulfoalkylresorcinol	0
terbutaline +	0
vaccihein A	0
vedelianin +	0
violaceol II	0
zearalenone +	273
Path 2
Term	Annotations
CHEBI ontology	5081
subatomic particle	5072
composite particle	5072
hadron	5072
baryon	5072
nucleon	5072
atomic nucleus	5072
atom	5072
main group element atom	5042
p-block element atom	5039
carbon group element atom	4957
carbon atom	4956
organic molecular entity	4956
organic molecule	4903
organic cyclic compound	4841
organic aromatic compound	822
phenols	644
benzenediols	494
resorcinols	488
(+)-microdiplodiasone	0
(-)-(S)-chlorizidine A	0
(2R,4R,12S)-16,18-dihydroxy-12-methyl-3,13-dioxatricyclo[13.4.0.02,4]nonadeca-1(15),16,18-triene-8,14-dione	0
(2R,4R,12S)-16-hydroxy-18-methoxy-12-methyl-3,13-dioxatricyclo[13.4.0.02,4]nonadeca-1(15),16,18-triene-8,14-dione	0
(3,5-dihydroxyphenyl)acetic acid	0
(3R,4R)-7,2',4'-trihydroxyisoflavanol	0
(5S)-2-(3,5-dihydroxyphenyl)-5-hydroxy-3-methylcyclopent-2-en-1-one	0
(5S,6S,11S)-5,6,15-trihydroxy-17-methoxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,8,15,17-pentaene-7,13-dione	0
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside	0
(E)-Antibiotic BE 23372M	0
(S)-1-(3,5-dihydroxy-4-methylphenyl)-4-hydroxypentan-2-one	0
(S)-3,5-dihydroxyphenylglycine	0
(S,E)-1-(3,5-dihydroxyphenyl)-10-hydroxyundec-1-en-6-one	0
(S,E)-2,4-dihydroxy-6-(10-hydroxy-6-oxoundec-1-en-1-yl)benzoate	0
(S,E)-Zearalenone	0
1''-hydroxycannabidiol	0
1-(3,5-Dihydroxyphenyl)-2-pentadecanone	0
1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one	0
1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)pentan-1-one	0
1-(3,5-dihydroxyphenyl)-4-hydroxypentan-2-one	0
15,17-dihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),2,15,17-tetraene-7,13-dione	0
15-O-desmethyl-(5Z)-7-oxozeaenol	0
2''-hydroxycannabidiol	0
2',4'-dihydroxy-3'-(2-hydroxy benzyl)-6'-methoxy chalcone	0
2',4'-dihydroxy-3'-methyl-6'-methoxychalcone	0
2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone	0
2',4'-dihydroxyacetophenone	0
2',6'-dihydroxy-4'-methoxyacetophenone	0
2,4-Bis(3-methylbut-2-enyl)-5-pentylbenzene-1,3-diol	0
2-(2,4-dihydroxy-5-prenylphenyl)-5,6-methylenedioxybenzofuran	0
2-(2,4-dihydroxyphenyl)-5-(E)-propenylbenzofuran	0
2-Hydroxy-4-methoxy-6-[(4R,5S,7Z,10S)-4,5,10-trihydroxy-6-oxo-7-undecenyl]benzoic acid mu-lactone	0
2-Methyl-5-(8-pentadecenyl)-1,3-benzenediol	0
2-[2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl]-2-hydroxyacetic acid	0
2-hexyl-5-(5-hydroxypentyl)resorcinol	0
2-hexyl-5-(7-carboxyheptyl)resorcinol	0
2-hexyl-5-(7-hydroxyheptyl)resorcinol	0
2-hexyl-5-(7-oxoheptyl)resorcinol	0
2-hexyl-5-heptylresorcinol	0
2-hexyl-5-methylresorcinol	0
2-hexyl-5-pentylresorcinol	0
3''-hydroxycannabidiol	0
3,3',5-trihydroxybibenzyl	0
3,4,5-trihydroxy-6-[(14-hydroxy-3-methyl-1,7-dioxo-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-16-yl)oxy]oxane-2-carboxylic acid	0
3,5-dihydroxybenzoic acid	0
3,5-dihydroxyphenylglyoxylic acid	0
3,5-dimethylorsellinic acid	0
3-(3,5-dihydroxyphenyl)-1-propanoic acid sulphate	0
3-methylorsellinic acid	0
4''-hydroxycannabidiol	0
4-(2,4-dihydroxyphenyl)butan-2-one	0
4-(4-nitrophenylazo)resorcinol	0
4-Acetylzearalenone	0
4-Ethylresorcinol	0
4-O-demethylhypothemycin	0
4-O-methylxanthohumol	0
4-Vinylresorcinol	0
4-chloro-6-\{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl\}benzene-1,3-diol	0
4-hexylbenzene-1,3-diol	0
4-hydroxy-5-propionyl-1,3-di-O-methylpyrogallol	0
4-methyl-5-pentylbenzene-1,3-diol	0
4-n-Butylresorcinol	0
5''-hydroxycannabidiol	0
5'-hydroxyasperentin	0
5-((3Z,6Z,9Z,12Z,15Z,18Z)-henicosa-3,6,9,12,15,18-hexaen-1-yl)resorcinol	0
5-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaen-1-yl)resorcinol	0
5-((5Z,8Z,11Z)-heptadeca-5,8,11-trien-1-yl)resorcinol	0
5-((5Z,8Z,11Z,14Z)-heptadeca-5,8,11,14-tetraen-1-yl)resorcinol	0
5-((7Z,10Z,13Z,16Z)-nonadeca-7,10,13,16-tetraen-1-yl)resorcinol	0
5-((8Z,11Z)-heptadeca-8,11-dien-1-yl)resorcinol	0
5-((8Z,11Z)-nonadeca-8,11-dien-1-yl)resorcinol	0
5-((8Z,11Z,14Z)-heptadeca-8,11,14-trien-1-yl)resorcinol	0
5-((Z)-henicos-14-en-1-yl)resorcinol	0
5-((Z)-nonadec-8-en-1-yl)resorcinol	0
5-(1-amino-2-hydroperoxyethyl)benzene-1,3-diol	0
5-(10,13-Nonadecadienyl)-1,3-benzenediol	0
5-(12,15-Heneicosadienyl)-1,3-benzenediol	0
5-(12-Heptadecenyl)-1,3-benzenediol	0
5-(14-Nonadecenyl)-1,3-benzenediol	0
5-(3',4',5'-Trihydroxyphenyl)-gamma-valerolactone-4'-O-sulphate	0
5-(3',5')-Dihydroxyphenyl-gamma-valerolactone	0
5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide	0
5-(8,11,14-pentadecatrienyl)resorcinol	0
5-(hydroxymethyl)benzene-1,3-diol	0
5-Heneicosyl-1,3-benzenediol	0
5-Nonadecyl-1,3-benzenediol	0
5-Pentacosyl-1,3-benzenediol	0
5-Pentadec-8-enylbenzene-1,3-diol	0
5-[(10E)-Nonadec-10-en-1-yl]benzene-1,3-diol	0
5-[(10Z)-14-(3,5-dihydroxyphenyl)tetradec-10-en-1-yl]benzene-1,3-diol	0
5-[(3E,5E)-3,5-nonadienyl]-1,3-benzenediol	0
5-[(3Z,5E)-3,5-nonadienyl]-1,3-benzenediol	0
5-[(8Z,11Z)-pentadeca-8,11-dien-1-yl]benzene-1,3-diol	0
5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol +	0
5-[12-(3,5-Dihydroxyphenyl)dodecyl]benzene-1,3-diol	0
5-alkatrienylresorcinol +	0
5-alkenylresorcinol +	0
5-alkylresorcinol +	0
5-heptadeca-8′Z,11′Z,16-trienylresorcinol	0
5-heptadeca-9′E,11′Z,16-trienylresorcinol	0
5-methylorsellinic acid	0
5-nonacosylresorcinol	0
5′beta-hydroxyzearalenone	0
6'-O-desmethylterphenyllin	0
6-(2,4-dihydroxyphenyl)-2-(2,6-dihydroxyphenyl)-6-hydroxy-4-methylcyclohex-3-ene-1-carboxylic acid	0
6-[2-(2,4-dihydroxy-6-methylphenyl)-2-oxoethyl]-4-hydroxy-pyran-2-one	0
6-demethylsorbicillin	0
6alpha-hydroxycannabidiol	0
6beta-hydroxycannabidiol	0
7'beta-hydroxyzearalenone	0
7-hydroxycannabidiol	0
8'-hydroxyzearalanone	0
9′alpha-hydroxyzearalenone	0
Adipostatin B	0
Aigialomycin A	0
Albaconol	0
Ascotrichrone A	0
Aspulvinone O	0
CCT-018159	0
Cardol diene	0
Chaetosemin J	0
Cochliomycin D	0
Cochliomycin E	0
Cochliomycin F	0
Cytosporone F	0
Cytosporone T	0
Cytosporone U	0
Demethylsorbicillin	0
Grevillol	0
Hamigeromycin A	0
Hamigeromycin B	0
Hamigeromycin C	0
Hamigeromycin D	0
Hamigeromycin E	0
Hansfordiol B	0
Hansfordiol F	0
ICPD-26	0
ICPD-47	0
Ilyoresorcy G	0
Ilyoresorcy I	0
Integramycin	0
Javanicol C	0
L-783277	0
LL-Z1640-1	0
Microcarbonin A	0
Monavalerolactone	0
Neocosmosin B	0
Neocosmosin C	0
Nostolactone 4	0
Paecilomycin N	0
Paecilomycin O	0
Penicipyran B	0
Peniquinone B	0
Precochlioquinol D	0
Pyrogallol-2-O-sulphate	0
Raistrickione E	0
Resorcinin	0
SCHEMBL7458752	0
Saccharothriolide B	0
Saccharothriolide C	0
Saccharothriolide C2	0
Saccharothriolide E	0
Sch 725681	0
Stemphol	0
TAN-931	0
Terbutaline-1-sulfate	0
Trichosorbicillin I	0
Venemycin	0
Zearalanone	0
Zearalenone 4-sulfate	0
Zobelliphol	0
abyssinone A	0
abyssinone C	0
abyssinone D	0
abyssinone VI	0
alpha-aminoorcein +	0
alpha-hydroxyorcein +	0
anolignan A	0
ardisiphenol A	0
ardisiphenol B	0
ardisiphenol C	0
arugosin A (hydroxy-aldehyde form)	0
ascochlorin	0
ascofuranol	0
ascofuranone	0
asperentin +	0
beta-aminoorceimine +	0
beta-aminoorcein +	0
beta-hydroxyorcein +	0
brartemicin	0
candidachalcone	0
cannabidiol +	0
cannabidiolic acid	0
cannabigerol	0
cannabigerolic acid	0
cannabinerolic acid	0
cephalanone F	0
clavatol +	0
comazaphilone D	0
cytonic acid A	0
cytonic acid B	0
dihydropinosylvin	0
diuvaretin	0
drummondin E	0
eriosemaone C	0
eucalyptal A	0
eucalyptal B	0
eucalyptal C	0
fenoterol +	0
flamenol	0
flavan-3,3',4,4',5,5',7-heptol +	0
furanocandin	0
gaboroquinone A	0
gamma-aminoorceimine +	0
gamma-aminoorcein +	0
gamma-hydroxyorcein +	0
gancaonin I	0
globosumone A	0
globosumone B	0
globosumone C	0
glycycoumarin	0
hydroxyclavatol +	0
hydroxyclavatol ethyl ether	0
hydroxyclavatol methyl ether	0
ilicicolin B	0
integracin A	0
integracin B	0
integracin C	0
isoliquiritin	0
knipholone +	0
kuraridinol	0
kuwanone G	1
kuwanone H	0
leptorumol	0
licoarylcoumarin	0
licocoumarone	0
licodione +	0
littorachalcone	0
luminespib	0
methylophiopogonone A	0
methylophiopogonone B	0
monodictyphenone	0
multifidol glucoside	0
naringin chalcone	0
noreugenin	0
o-orsellinic acid +	0
olivetol +	0
olivetolic acid +	0
onalespib	0
pacein	0
penilactone A	0
penilactone B(1-)	0
penilactone D(2-)	0
peniphenone D(1-)	0
phlorizin chalcone	0
piceatannol +	0
pisonin B	0
pisonin C	0
pisonin F	0
platensimycin A1 methyl ester	0
platensimycin A2 methyl ester	0
platensimycin A3 methyl ester	0
platensimycin A4 methyl ester	0
platensimycin B1	0
platensimycin B3	0
pyoluteorin	0
resorcinol +	0
resveratrol +	226
riodoxol	0
rohitukine	0
schweinfurthin E	0
schweinfurthin F	0
schweinfurthin G	0
soppiline B	0
soppiline C	0
sorocenol H	0
sulfoalkylresorcinol	0
terbutaline +	0
vaccihein A	0
vedelianin +	0
violaceol II	0
zearalenone +	273

paths to the root